Library › Hemostasis and coagulation laboratory testing
Hemostasis and coagulation laboratory testing
Last reviewed 2026-11-10 by a board-certified pathologist. 186 references.
Coagulation Specimen Collection, Screening Tests and Mixing Studies
Definition. Coagulation screening tests are clot-based assays performed on citrated platelet-poor plasma: the prothrombin time (PT) with the international normalized ratio (INR), the activated partial thromboplastin time (aPTT), the thrombin time (TT) and the fibrinogen assay. D-dimer measures fibrin breakdown. The mixing study separates a factor deficiency from an inhibitor when a clotting time is prolonged. The International Council for Standardization in Haematology (ICSH) published recommendations on collection of samples for coagulation testing in 2021. These cover the collection tube and anticoagulant, patient preparation, venous stasis, order of draw, labeling, tube filling and the influence of hematocrit (Kitchen 2021a). A companion ICSH document covers transport, centrifugation, primary tube stability, hemolysis, icterus and lipemia, secondary aliquots and platelet function specimens (Kitchen 2021b).
Related page: Clotting Factor Assays, Factor Inhibitors and Interference by Hemophilia Therapies (single-factor assays, Bethesda assay and hemophilia therapies) Related page: Von Willebrand Factor Testing and Platelet Function Testing (von Willebrand factor and platelet function testing) Related page: Thrombophilia Testing and Antiphospholipid Antibody Testing (lupus anticoagulant testing) Related page: Anticoagulant Monitoring, DOAC Measurement and Heparin-Induced Thrombocytopenia Testing (heparin and direct oral anticoagulant measurement) Related page: DIC, Thrombotic Microangiopathy and Viscoelastic Testing (disseminated intravascular coagulation and viscoelastic testing) Related page: Transfusion Indications, Massive Transfusion, Platelet Refractoriness and Patient Blood Management (plasma, cryoprecipitate and fibrinogen replacement)
Hemostasis models used to interpret clot-based tests
The cell-based model describes coagulation in vivo as three overlapping stages. Initiation occurs on a tissue factor-bearing cell. Amplification activates platelets and cofactors. Propagation generates large amounts of thrombin on the platelet surface (Hoffman 2001). In this model, cell surface receptors regulate coagulation, and the protein cascade alone does not explain hemostasis (Hoffman 2001).
Plasma clotting tests omit cells and are interpreted with the classic protein pathways.
| Test | Reagent | Factors assessed | Source |
|---|---|---|---|
| PT | Tissue factor ("thromboplastin"), phospholipid and calcium chloride | II, V, VII, X and fibrinogen | Bronić 2019 |
| aPTT | Contact activator (silica, kaolin or ellagic acid) and phospholipid without tissue factor; calcium added separately | VIII, IX, XI and XII; prekallikrein and high-molecular-weight kininogen are contact proteins | Bronić 2019; Jacobs 2026a |
| PT and aPTT together | Both reagents | Common pathway: II, V, X and fibrinogen | Androulakis 2026 |
| TT | Excess bovine or human thrombin added to plasma | Conversion of fibrinogen to fibrin; thrombin inhibitors | Bronić 2019 |
The plasma contact system consists of factor XII, prekallikrein, factor XI and high-molecular-weight kininogen. Factor XII undergoes autoactivation on a negatively charged surface, and kallikrein amplifies further factor XII activation (Jacobs 2026a).
The PT, aPTT and INR do not reliably predict perioperative bleeding in patients without known bleeding risk factors. The bleeding history and examination identify risk factors, and the tests remain in wide use for anticoagulant monitoring (Levy 2014).
Citrate anticoagulant and tube filling
- Citrate concentration. The Clinical and Laboratory Standards Institute (CLSI) collection guideline recommends sodium citrate at 105–109 mmol/L (3.2%), with plasma pH 7.3–7.45 (Magnette 2016). Tubes of 129 mmol/L (3.8%) citrate bind more calcium and prolong clotting times (Magnette 2016). With responsive reagents, citrate concentration changed the INR of patients on oral anticoagulants and the aPTT of patients on intravenous heparin. Adcock and colleagues recommended 3.2% citrate for all coagulation tests on the basis of these data (Adcock 1997).
- Blood-to-anticoagulant ratio. The ratio is 9:1 (blood to citrate), and citrate tubes are filled to at least 90% of the nominal volume or to the mark on the tube (Magnette 2016).
- Effect of underfilling. Clinically significant bias appears in the aPTT below 89% fill, in fibrinogen below 78% and in factor VIII below 67%. The PT and activated protein C resistance remain relatively reliable at 67% fill (Magnette 2016). In 3.2% citrate, PT results did not differ between 60% and 100% fill and aPTT results did not differ between 70% and 100% fill. The effect of underfilling was greater in 3.8% citrate (Adcock 1998).
- Discard tube. CLSI considers a discard tube unnecessary for routine coagulation assays. A discard tube is drawn when citrated plasma is collected through a butterfly system or catheter, so that the dead space does not underfill the citrate tube (Magnette 2016).
- Order of draw. Blood culture or sterile tubes are drawn first, then coagulation tubes, then plain or gel tubes and then tubes with other additives (Magnette 2016).
- Tourniquet. The tourniquet is applied for less than 1 minute. Longer stasis causes hemoconcentration and increases fibrinogen and factors VII, VIII and XII (Magnette 2016).
Citrate adjustment for high hematocrit
At a hematocrit above 0.55 L/L, the plasma volume is reduced and the citrate is in excess for the plasma in the tube. The citrate volume is adjusted to restore a 9:1 blood-to-anticoagulant ratio (Bronić 2019). In samples from patients with hematocrits of 0.55–0.72, PT and aPTT results from adjusted and nonadjusted tubes differed and rose exponentially with hematocrit. Fibrinogen, factor VIII and protein C activity also differed, with smaller clinical effect (Marlar 2006).
| Step | Specification | Source |
|---|---|---|
| Threshold | Hematocrit >0.55 L/L | Bronić 2019 |
| Citrate to leave in the tube | C (mL) = 0.185 × V × (1.0 − Hct), where V is the blood volume of the tube (mL) and Hct is in L/L | Bronić 2019 |
| Example | V = 4.5 mL and Hct = 0.65: C = 0.185 × 4.5 × 0.35 = 0.29 mL | Calculated from Bronić 2019 |
| Removal | Excess citrate is withdrawn with a tuberculin syringe to keep the vacuum | Bronić 2019 |
| Report comment | States that the citrate volume was adjusted for a high hematocrit and gives the hematocrit | Bronić 2019 |
Transport, centrifugation and storage of coagulation specimens
- Temperature before testing. Specimens are kept capped at 18–25 °C. Refrigeration of whole blood can activate factor VII and lowers factor VIII and VWF, which can falsely suggest hemophilia A or von Willebrand disease (VWD) (Bronić 2019; Magnette 2016).
- Transport. Samples are transported upright, without shaking, at ambient temperature and preferably within 1 hour. A dropped sample is discarded. Results from pneumatic tube transport are not used for platelet function or aspirin responsiveness decisions (Magnette 2016).
- Centrifugation. Primary tubes are spun at 1500 g for at least 15 minutes at 15–25 °C with the brake off. Forces above 1500 g can activate platelets and cause hemolysis. Higher force for less than 10 minutes is acceptable in emergencies for the PT, aPTT and fibrinogen on fresh plasma (Magnette 2016).
- Platelet-poor plasma. Double centrifugation produces a residual platelet count of 10 × 10⁹/L or less. Residual platelets release phospholipid that neutralizes lupus anticoagulant (LA) activity, especially after freezing (Magnette 2016).
| Test | Time limit from collection | Source |
|---|---|---|
| PT/INR and D-dimer | Up to 24 hours at ambient temperature, uncentrifuged or with plasma left on cells in an unopened tube | Bronić 2019; Magnette 2016 |
| aPTT | Within 4 hours | Magnette 2016 |
| aPTT for unfractionated heparin (UFH) monitoring | Centrifuged and plasma removed within 1 hour in citrate tubes | Bronić 2019; Magnette 2016 |
| Factors V and VIII | Within 3 hours | Magnette 2016 |
| Fibrinogen, protein C, antithrombin activity | Relatively constant at room temperature for up to 7 days | Magnette 2016 |
| Protein S activity | Significant loss of activity at 8 hours | Magnette 2016 |
The short stability of heparinized samples reflects neutralization of heparin by platelet factor 4 released from platelets (Magnette 2016).
Frozen plasma. Plasma that cannot be tested within 4 hours is centrifuged, aliquoted and frozen. Storage at −70 °C or below is preferred to −20 °C. Plasma at −20 °C is stable for about 2 weeks for most parameters, and plasma at −80 °C for 6–18 months depending on the analyte. Frozen plasma is thawed rapidly at 37 °C, mixed gently and not refrozen (Magnette 2016).
Hemolysis, icterus and lipemia in optical clot detection
| Interferent | Mechanism | Effect | Source |
|---|---|---|---|
| Spurious hemolysis | Absorbance by cell-free hemoglobin; release of tissue factor, phospholipid and ADP that activate coagulation and platelets | Results on spuriously hemolyzed specimens are suppressed | Lippi 2013 |
| Spurious hemolysis (269 paired samples) | Bias beyond the critical difference in 36.1% for aPTT and 17.1% for D-dimer; less than 8% for PT, fibrinogen and antithrombin | aPTT and D-dimer most affected; PT only slightly affected | Novelli 2018 |
| Icterus | Spectral overlap | Analyzers reading at 650 nm or above give reliable results up to a bilirubin of 20 mg/dL | Lippi 2013 |
| Lipemia | Light scatter, volume displacement and direct lipid interference | Greatest below 500 nm; reduced at 650 nm or above or with higher sample dilution; high-speed centrifugation or lipid extraction above 1,000 mg/dL triglycerides | Lippi 2013 |
Mechanical or electromechanical clot detection is used for lipemic and icteric plasma when available (Magnette 2016). Hemolysis is the most common reason for rejection of coagulation specimens (Magnette 2016).
Prothrombin time and international normalized ratio
PT reagents contain tissue factor, phospholipid and calcium chloride. The World Health Organization (WHO) introduced the INR to standardize PT results for vitamin K antagonist monitoring between laboratories. Manufacturers assign each reagent lot an international sensitivity index (ISI) against the WHO international reference preparation (Bronić 2019).
| Element | Definition | Source |
|---|---|---|
| INR formula | INR = (patient PT / MNPT)ISI | Bronić 2019 |
| MNPT | Mean normal prothrombin time: the geometric mean PT of at least 20 healthy volunteers, determined locally | Bronić 2019 |
| ISI | Sensitivity of the reagent to reduced vitamin K-dependent factors relative to the WHO reference | Bronić 2019 |
| Reagent choice | Recombinant thromboplastins with ISI below 1.2 | Bronić 2019 |
| Instrument-specific ISI | Used when available; determined locally when unavailable | Bronić 2019 |
| Direct INR method | Lyophilized plasmas with certified INR values calibrate the reagent and analyzer combination | Bronić 2019 |
Point-of-care INR. Point-of-care devices measure the INR in a fingerstick whole blood sample and allow patient self-testing and self-management (Medical Advisory Secretariat 2009). Their limitations include underestimation of high INR values, overestimation of low INR values, low thromboplastin sensitivity and no calculation of a local MNPT (Medical Advisory Secretariat 2009). In 17 pooled randomized trials, patients managed with point-of-care INR monitoring had fewer thromboembolic events than patients in usual care (odds ratio 0.52, 95% CI 0.37–0.74) (Medical Advisory Secretariat 2009).
Activated partial thromboplastin time
aPTT reagents differ in activator and phospholipid. Their sensitivities to factor deficiency, UFH and LA therefore differ, and results depend on the reagent and instrument. A screening aPTT reagent is chosen for sensitivity to factor deficiency and UFH and need not be sensitive to LA (Bronić 2019).
- UFH monitoring. The aPTT therapeutic interval for UFH is set locally against anti-Xa activity (Bronić 2019). Calibration and low-molecular-weight heparin monitoring are described in Anticoagulant Monitoring, DOAC Measurement and Heparin-Induced Thrombocytopenia Testing.
- Prekallikrein deficiency. Prolonged incubation of prekallikrein-deficient plasma with a silica reagent shortens or normalizes the aPTT. This incubation effect separates prekallikrein deficiency from deficiencies of factor XII, factor XI and high-molecular-weight kininogen. In one patient with an aPTT of 87.4 s, the aPTT corrected with normal plasma and did not correct with prekallikrein-deficient plasma. Prekallikrein deficiency prolongs the aPTT without a bleeding phenotype (Jacobs 2026a).
- Activated clotting time. The point-of-care activated clotting time and its targets in cardiopulmonary bypass are described in Anticoagulant Monitoring, DOAC Measurement and Heparin-Induced Thrombocytopenia Testing.
Thrombin time, reptilase time and fibrinogen assays
- Thrombin time. The TT measures conversion of fibrinogen to fibrin after excess thrombin is added. It detects hypofibrinogenemia, qualitative fibrinogen disorders and thrombin inhibitors. It detects heparin contamination at concentrations above 0.05 IU/mL anti-Xa. Its sensitivity to heparin and dabigatran makes it unsuitable for monitoring either drug (Bronić 2019).
- Reptilase time. Reptilase is not inhibited by antithrombin. A prolonged TT with a normal reptilase time is the classic finding of heparin or a direct thrombin inhibitor (Alotaibi 2026). The reptilase or atroxin time excludes heparin contamination before a hypofibrinogenemia or dysfibrinogenemia is confirmed (Besser 2016).
- Reptilase time in dysfibrinogenemia. Reptilase cleaves only fibrinopeptide A, and this cleavage site is the most common site of defects in congenital dysfibrinogenemia. The reptilase time can therefore be more prolonged than the TT (Saadalla 2025), and it is highly prolonged in most dysfibrinogenemias (Gindele 2021). A prolonged TT with a prolonged reptilase time indicates a fibrinogen disorder (Saadalla 2025).
- Clauss fibrinogen. Diluted plasma is clotted with a high concentration of thrombin, so that the clotting time depends on fibrinogen concentration. The result is read from a calibration curve. The Clauss assay is the reference method for functional fibrinogen. It underestimates at very low concentrations, and high-concentration UFH and direct thrombin inhibitors can give falsely low values. An adult interval of about 1.5–4.0 g/L is widely accepted, and each laboratory verifies its own (Alotaibi 2026).
- PT-derived fibrinogen. The PT-derived fibrinogen is calculated from the optical or mechanical signal change during the PT reaction (Alotaibi 2026). The Croatian national recommendations do not recommend it for routine use (Bronić 2019). A low Clauss fibrinogen with a normal PT-derived fibrinogen and a prolonged TT indicates a qualitative fibrinogen defect (Alotaibi 2026). Activity-to-antigen ratios are covered in Clotting Factor Assays, Factor Inhibitors and Interference by Hemophilia Therapies.
Mixing studies for prolonged PT and aPTT
A mixing study combines patient plasma with normal pooled plasma (NPP). Correction indicates factor deficiency, and noncorrection indicates an inhibitor (Gosselin 2024). Protocols and interpretation are not standardized (Adcock 2023).
- Standard method. Equal volumes of patient plasma and NPP are mixed, and the clotting time is measured immediately and after 1–2 hours at 37 °C (Androulakis 2026).
- Time-dependent inhibitors. Inhibitors in acquired hemophilia A are time and temperature dependent, so immediate and 2-hour incubated results are compared. Mixing tests cannot establish or exclude acquired hemophilia A, and factor assays are performed in parallel (Tiede 2020).
- Dilution of weak inhibitors. A 1:1 mix can appear to correct because weak inhibitors, low-titer LA or residual anticoagulant are diluted (Androulakis 2026).
- 4:1 mix. A 4:1 mix of patient plasma with NPP, assessed by percent correction, had better sensitivity and specificity than a 1:1 mix (Chang 2002).
- Indication threshold. The 2024 ICSH recommendations on mixing tests advise against mixing studies for minimal prolongation, and cutoffs of ≥3 SD above the mean have been suggested (Adcock 2024, as summarized by Androulakis 2026).
| Index | Formula | Interpretation | Source |
|---|---|---|---|
| Rosner index (index of circulating anticoagulant) | [(mix CT − NPP CT) / patient CT] × 100 | Below 12–15% indicates correction | Formula: Rosner 1987; cutoff: Androulakis 2026 |
| Percent correction (Chang) | [(patient CT − mix CT) / (patient CT − NPP CT)] × 100 | ≥70% suggests deficiency | Formula: Chang 2002; cutoff: Androulakis 2026 |
| Subtraction method III | Mix CT − NPP CT, with NPP run concurrently | ≤0 indicates correction | Gosselin 2024 |
CT, clotting time.
ICSH field study (2024). Percent correction was the most suitable method for PT mixing tests. Incubated PT mixing tests are not performed. For aPTT mixing, percent correction is calculated first, and a result indicating deficiency is confirmed by subtraction method III. No single method separated deficiencies from inhibitors consistently, and results varied between reagents and sites (Gosselin 2024).
D-dimer and fibrinolysis
Plasmin cleaves fibrinogen and fibrin into fibrin(ogen) degradation products. D-dimer is the smallest fragment and arises only from digestion of crosslinked fibrin, so it reflects both clot formation and fibrinolysis. Its plasma half-life is about 16 hours. α2-antiplasmin is the main plasmin inhibitor and forms the plasmin–antiplasmin complex (Zheng 2023). A normal D-dimer has a high negative predictive value for deep vein thrombosis and pulmonary embolism (Zheng 2023).
- Units. D-dimer methods use different antibodies, units and cutoffs, and results are not comparable between methods. Results in fibrinogen-equivalent units (FEU) are about twice those in D-dimer units (DDU): 1.0 mg/L FEU is about 0.5 mg/L DDU. Kits that do not state the unit type are not used (Bronić 2019).
- Reporting errors. In College of American Pathologists proficiency testing from 2020 to 2023, laboratories often reported units that differed from the package insert. For one instrument-reagent combination, most results differed from the certificate of analysis by about twofold (Salazar 2026).
- Age-adjusted cutoff. ADJUST-PE validated a cutoff of age × 10 µg/L in patients 50 years or older with a nonhigh or unlikely clinical probability of pulmonary embolism. Among patients with D-dimer between 500 µg/L and the age-adjusted cutoff who were left untreated, the 3-month failure rate was 1 of 331 (0.3%) (Righini 2014). The 500 µg/L and age × 10 cutoffs apply to assays reporting in FEU (Westafer 2023; Fatah 2026). For assays reporting in DDU, the conventional cutoff is 250 µg/L and the age-adjusted cutoff is age × 5 µg/L (Fatah 2026). Westafer and colleagues state that it is unclear whether the age × 5 threshold applies to all DDU assays (Westafer 2023).
Developmental hemostasis and pediatric reference intervals
- Full-term infants. Coagulation test results vary with postnatal age. Factors mature at different rates, and most components reach near-adult values by 6 months (Andrew 1987).
- Analyzer-specific intervals. Absolute pediatric reference ranges vary with analyzer and reagent. Each laboratory develops age-related ranges for its own system (Monagle 2006). The International Society on Thrombosis and Haemostasis (ISTH) also recommends that each laboratory define age-dependent reference ranges under its own conditions (Gorio 2025).
- Neonatal values. Vitamin K-dependent factors II, VII, IX and X, protein C and protein S are reduced at birth. Factor IX matures at about 9–12 months, which complicates diagnosis of moderate and mild hemophilia B. Antithrombin, protein C and plasminogen are about 50% of adult levels at birth. VWF activity and ultra-large multimers are increased (Gorio 2025).
Interpretation of screening test patterns in the bleeding patient
| Pattern | Causes | Source |
|---|---|---|
| Isolated prolonged PT | Factor VII deficiency | Bronić 2019; Mohsenian 2026 |
| Isolated prolonged aPTT | Deficiency of factor VIII, IX, XI or XII; prekallikrein deficiency; acquired factor VIII inhibitor; LA or UFH, depending on reagent sensitivity | Bronić 2019; Jacobs 2026a; Tiede 2020 |
| Prolonged PT and aPTT | Deficiency of factor II, V or X or fibrinogen; chronic liver disease | Androulakis 2026; Agouba 2026 |
| Prolonged TT, normal reptilase time | Heparin or a direct thrombin inhibitor | Alotaibi 2026 |
| Prolonged TT and prolonged reptilase time | Hypofibrinogenemia or dysfibrinogenemia | Alotaibi 2026; Saadalla 2025 |
| Normal PT, aPTT, TT and fibrinogen with bleeding | Factor XIII deficiency; VWD; platelet function disorders | Jacobs 2026b; Tosetto 2026 |
- Factor XIII deficiency. Screening findings and factor XIII assays are described in Clotting Factor Assays, Factor Inhibitors and Interference by Hemophilia Therapies.
- VWD. A prolonged aPTT occurs in VWD when factor VIII is reduced, and a normal aPTT does not exclude VWD (Tosetto 2026).
- Liver disease. Factor patterns in liver disease are described in Clotting Factor Assays, Factor Inhibitors and Interference by Hemophilia Therapies.
- Factor VII deficiency. Bleeding risk by factor VII activity is described in Clotting Factor Assays, Factor Inhibitors and Interference by Hemophilia Therapies.
coagulation screening test pattern lookup
Clotting Factor Assays, Factor Inhibitors and Interference by Hemophilia Therapies
Definition. Clotting factor assays measure the activity of a single coagulation factor in plasma. The one-stage clot-based assay (OSA) is a modified aPTT or PT performed with factor-deficient plasma. The chromogenic substrate assay (CSA) measures factor Xa generation with a color-producing substrate (Bowyer 2023). Factor inhibitors are antibodies that neutralize a coagulation factor. They arise as alloantibodies in hemophilia treated with factor concentrates, or as autoantibodies in acquired hemophilia A (Miller 2018; Tiede 2020). Extended half-life (EHL) factor concentrates, gene therapy, the factor VIII mimetic emicizumab and the rebalancing agents fitusiran and concizumab each affect the laboratory measurement of factor activity, inhibitors or drug effect (Bowyer 2023; Hemlibra label 2025; Qfitlia label 2025; Alhemo label 2025).
Related page: Coagulation Specimen Collection, Screening Tests and Mixing Studies (specimen requirements, screening patterns and mixing studies) Related page: Von Willebrand Factor Testing and Platelet Function Testing (von Willebrand factor testing and type 2N VWD) Related page: Thrombophilia Testing and Antiphospholipid Antibody Testing (lupus anticoagulant testing) Related page: DIC, Thrombotic Microangiopathy and Viscoelastic Testing (fibrinogen in DIC and viscoelastic testing) Related page: Transfusion Indications, Massive Transfusion, Platelet Refractoriness and Patient Blood Management (plasma, cryoprecipitate and fibrinogen replacement)
One-stage, chromogenic and two-stage factor assay methods
- One-stage clot-based assay. Diluted patient plasma is added to plasma that lacks the factor being measured. Factor in the patient plasma shortens the clotting time of the deficient plasma. The clotting times are compared with a reference or calibrator plasma on a calibration curve (Bowyer 2023).
- Chromogenic factor VIII assay. Factor VIII in the sample is activated and, with added factor IXa, activates factor X. Factor Xa cleaves a chromogenic substrate, and the color change is proportional to factor VIII. Kits differ in the source of reagents (human, bovine or mixed), phospholipid, buffers and incubation time (Bowyer 2023).
- Two-stage clotting assay. The two-stage clotting assay is now performed in only a few specialized laboratories (Bowyer 2023).
- Chromogenic factor IX assays. No chromogenic factor IX reagent has been approved by the US Food and Drug Administration (FDA) for clinical use (Miller 2018).
| Variable | Requirement or effect | Source |
|---|---|---|
| Calibration | Calibrators traceable to a WHO, NIBSC or ISTH standard; OSA curves usually use 5–7 points | Bowyer 2023 |
| Dilutions | At least 3 dilutions of patient plasma for the OSA; a single dilution for the CSA | Bowyer 2023 |
| Nonparallelism | Some drugs mimic a factor inhibitor and give nonparallel dilution curves | Bowyer 2023 |
| Low activity range | Dual OSA set-ups on analyzers improve accuracy below 15 IU/dL | Bowyer 2023 |
| Anticoagulants | Heparins, parenteral direct thrombin inhibitors and DOACs can lead to underestimated activity in either method; heparin neutralizers and higher dilution reduce the effect in some CSAs | Bowyer 2023 |
| Nonspecific inhibitors | Lupus anticoagulant (LA) and lipoglycopeptide antibiotics interfere with the OSA; dilution reduces the effect | Bowyer 2023 |
| aPTT reagent | Activator (silica, kaolin, ellagic acid) and phospholipid source alter responsiveness, especially to EHL products | Bowyer 2023 |
Hemophilia A and B severity classification
| Severity | Factor VIII or IX activity | Source |
|---|---|---|
| Severe | <1 IU/dL | Bowyer 2023 |
| Moderate | 1–5 IU/dL | Bowyer 2023 |
| Mild | >5 to <40 IU/dL | Bowyer 2023 |
Patients with severe hemophilia have spontaneous bleeding, including hemarthroses. Patients with moderate hemophilia bleed after minor trauma, and patients with mild hemophilia bleed mainly after significant trauma or surgery (Bowyer 2023).
One-stage and chromogenic discrepancy in nonsevere hemophilia A
- Variants causing discrepancy. More than 20 F8 variants are linked to significant differences between OSA and CSA or two-stage results. The first report, in 1983, described an OSA result twofold or more higher than the two-stage result (Bowyer 2023).
- OSA higher than CSA. Factor VIIIa that is unstable is inactivated during the longer CSA incubation, so the CSA result is lower (Bowyer 2023).
- Reverse discrepancy. About 10 F8 variants give a lower OSA than CSA. p.Tyr365Cys/Phe slows thrombin activation of factor VIII and is frequently reported in the United Kingdom (Bowyer 2023).
- Testing strategy. One normal and one reduced result can delay diagnosis, so both OSA and CSA are measured when mild hemophilia A is suspected. The bleeding phenotype generally follows the lower value (Bowyer 2023).
- Hemophilia B. Assay discrepancy is rare. When present, for example with p.Arg191His or p.Arg191Cys, it can move patients between the moderate and mild categories (Bowyer 2023).
Hemophilia carriers and women and girls with hemophilia
Through lyonization, carriers have a median factor VIII or IX level of 0.60 IU/mL (range 0.05–2.19), compared with 1.02 IU/mL in noncarriers. Levels from 0.60 to 0.05 IU/mL were increasingly associated with bleeding after tooth extraction, tonsillectomy and other operations (Plug 2006).
Current nomenclature (ISTH 2021). The ISTH Scientific and Standardization Committee (SSC) defined 5 categories: severe, moderate and mild hemophilia, symptomatic hemophilia carrier and asymptomatic hemophilia carrier (van Galen 2021). Females with factor VIII or IX activity below 0.40 IU/mL are classified as women and girls with hemophilia and graded with the male severity thresholds. Carriers with factor levels above 0.40 IU/mL are classified by bleeding phenotype (van Galen 2021). About 28% of carriers have factor levels below 0.40 IU/mL (van Galen 2021).
Previous rule. All heterozygous females were called hemophilia carriers regardless of factor level or bleeding (van Galen 2021).
- Assay choice in carriers. In one study, 14% of female hemophilia A carriers would not have received a diagnosis of hemophilia (factor VIII <40 IU/dL) with the OSA alone, and 2% with the CSA alone (Eswaran 2026).
Factor activity with standard, extended half-life and gene therapy products
- B-domain-deleted factor VIII. An OSA calibrated with plasma can measure B-domain-deleted recombinant factor VIII 20–50% lower than expected. A product-specific reference or a CSA reduces the difference (Bowyer 2023).
- EHL factor VIII. Glycopegylated factor VIII was underestimated by up to 50% with one silica-activated aPTT reagent. Site-specific pegylated factor VIII was underestimated by some silica reagents and overestimated by some kaolin reagents. The CSA gave acceptable recovery with all licensed EHL factor VIII products (Bowyer 2023).
- EHL molecules with the same modification. Two EHL molecules that use the same modification do not necessarily affect a given aPTT reagent in the same way (Bowyer 2023).
- Standard and extended half-life products. In one study, samples containing 3 factor VIII products (NovoEight, Nuwiq and the EHL product rFVIIIFc) gave higher levels by CSA than OSA, with biases of 42–72% of the mean. The factor IX Fc fusion product showed only a small bias. The authors noted that CSA results for recombinant factor IX products are generally about 30% lower than OSA results (Augustsson 2020).
- Gene therapy for hemophilia A. OSA factor VIII activity is about 1.6-fold higher than CSA activity after some gene therapy products. FDA guidance for hemophilia gene therapy requires testing with both chromogenic and one-stage assays (Bowyer 2023).
- Gene therapy for hemophilia B. After etranacogene dezaparvovec, which expresses factor IX-Padua, the CSA:OSA ratio was 0.408–0.547. Local and central OSA results differed modestly, and the same assay platform is used throughout follow-up (Astermark 2025).
| Product type | OSA versus CSA discrepancy | OSA reagent dependence | Source |
|---|---|---|---|
| EHL factor VIII | Yes | Yes | Bowyer 2023 |
| EHL factor IX | Yes | Yes | Bowyer 2023 |
| Factor VIII gene therapy | OSA about 1.6-fold higher than CSA | Yes | Bowyer 2023 |
| Factor IX-Padua gene therapy | CSA about 40–55% of OSA | Modest between OSA methods | Astermark 2025 |
Bethesda and Nijmegen-Bethesda inhibitor assays
Principle. A test mixture of patient plasma and a factor source and a control mixture of diluent and factor source are incubated in parallel. The residual activity (RA) of the test mixture is compared with the control. Factor VIII inhibitor assays require a defined incubation, and factor IX inhibitor assays do not (Miller 2018).
| Step in development | Change | Source |
|---|---|---|
| 1959 (Biggs and Bidwell) | Two-stage assay; 1-hour incubation; 1 unit destroyed 75% of factor VIII | Miller 2018 |
| 1975 (Bethesda) | 1 Bethesda unit (BU) = the amount of inhibitor in 1 mL of patient plasma that destroys 50% of the factor VIII activity of an equal volume of normal pooled plasma (NPP) in 2 hours at 37 °C; one-stage endpoint; imidazole buffer in the control | Miller 2018; Tiede 2020 |
| 1995 (Nijmegen) | NPP buffered with 0.1 M imidazole to pH 7.4; factor VIII-deficient plasma replaces buffer in the control mixture | Verbruggen 1995 |
| 2012 (CDC) | Preanalytical heat treatment of patient plasma removes infused or endogenous factor | Miller 2018 |
The Nijmegen modification stabilizes protein concentration and pH during incubation. It reduced low-titer positive results and was endorsed by the ISTH as the reference method (Miller 2018; Verbruggen 1995). Substitution of 4% bovine serum albumin for factor VIII-deficient plasma in the control mixture has been validated (Miller 2018).
Calculation of Nijmegen-Bethesda units
| Element | Rule | Source |
|---|---|---|
| Residual activity | %RA = (factor level of patient + NPP mix / factor level of diluent + NPP mix) × 100 | Miller 2018 |
| Titer | NBU = (2 − log %RA) / 0.301 | Miller 2018 |
| Undiluted sample | RA 25–100% is used as is; titers below 0.4 NBU (RA 75–100%) can be quantified down to the limit of detection | Miller 2018 |
| Diluted samples | When undiluted RA is <25% (>2.0 NBU), plasma is diluted until RA is 25–75%; NBU is multiplied by the dilution factor | Miller 2018 |
| Dilution reported | Usually the dilution with RA closest to 50%; some laboratories use the first dilution below 75% RA | Miller 2018 |
| Positive result | ≥0.6 NBU (ISTH SSC); ≥0.5 NBU validated for the CDC method | Miller 2018 |
| Limit of detection | 0.2 NBU for the CDC Nijmegen-Bethesda assay | Miller 2018 |
Inhibitor kinetics and sources of error in inhibitor assays
- Type 1 kinetics. Alloantibodies in congenital hemophilia A are completely neutralized by added factor VIII and show linear dilution behavior. Titers at different dilutions agree after multiplication (Miller 2018; Tiede 2020).
- Type 2 kinetics. Residual factor VIII activity persists despite large amounts of inhibitor. Similar RA at several dilutions gives progressively higher titers after multiplication. Autoantibodies in acquired hemophilia A often show complex type 2 kinetics, so the assay may not estimate their true potency (Miller 2018; Tiede 2020).
- Heat treatment. Heating plasma to 56 °C for 30 minutes separates antigen-antibody complexes and denatures factor VIII to below 1 IU/dL. Of 202 specimens negative before heating, 3% became positive after heating. Heat treatment increased detection of inhibitors in acquired hemophilia (Miller 2018).
- False positives. Among specimens with 0.5–1.9 NBU, 26% did not react in a chromogenic Bethesda assay or show anti-factor VIII antibodies. Heparin from central lines, LA and nonspecific inhibitors cause clot-based false positives (Miller 2018).
- Chromogenic Bethesda assay (CBA). The CBA uses a chromogenic factor VIII endpoint and is more specific for anti-factor VIII antibodies than the clot-based assay (Miller 2018).
- Immunoassays. ELISA and fluorescence immunoassays detect both neutralizing and non-neutralizing antibodies and cannot substitute for functional inhibitor assays (Miller 2018).
- Clinical definition. Recovery of less than 66% of the expected factor level 10–15 minutes after infusion indicates a clinically significant inhibitor (Miller 2018).
Laboratory diagnosis of acquired hemophilia A
Acquired hemophilia A is caused by neutralizing autoantibodies against factor VIII in persons without a previous bleeding history. Incidence peaks with pregnancy and after 60 years of age. About half of patients have a concomitant disorder, most often an autoimmune disease or malignancy (Tiede 2020).
| Finding | Value or rule | Source |
|---|---|---|
| Screening tests | Isolated prolonged aPTT; a prolonged PT has another cause, such as anticoagulant treatment | Tiede 2020 |
| Factor VIII activity at presentation | <1% in 50%, <5% in 75% and <40% in all cases | Tiede 2020 |
| Presentation without bleeding | About 10% of patients | Tiede 2020 |
| Mixing test | Cannot establish or exclude the diagnosis; methods in Coagulation Specimen Collection, Screening Tests and Mixing Studies | Tiede 2020 |
| Confirmation | Factor VIII activity with a Bethesda assay and/or anti-factor VIII ELISA (GRADE 1B) | Tiede 2020 |
| Low-titer method | Nijmegen modification | Tiede 2020 |
| LA | Can cause low-positive Bethesda results; chromogenic factor VIII assays are usually insensitive to LA; LA and acquired hemophilia A can coexist | Tiede 2020 |
| Anti-porcine inhibitor | Measured with a modified Bethesda assay when recombinant porcine factor VIII is considered; titers >20 BU excluded patients from the pivotal trial | Tiede 2020 |
Emicizumab interference with coagulation tests
Emicizumab is a humanized bispecific IgG4 antibody that binds factor IXa and factor X and mimics activated factor VIII (Hemlibra label 2025; Lowe 2020). The United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) guideline describes its effect on coagulation tests and gives recommendations for factor VIII, inhibitor and drug measurement (Jenkins 2020).
| Affected by emicizumab | Unaffected by emicizumab | Source |
|---|---|---|
| aPTT | Bethesda assay with a bovine chromogenic endpoint | Hemlibra label 2025 |
| Clot-based Bethesda assays | Thrombin time | Hemlibra label 2025 |
| One-stage aPTT-based single-factor assays | One-stage PT-based single-factor assays | Hemlibra label 2025 |
| aPTT-based activated protein C resistance | Chromogenic single-factor assays other than factor VIII | Hemlibra label 2025 |
| Activated clotting time | Immunoassays (ELISA, turbidimetric) and genetic tests such as factor V Leiden | Hemlibra label 2025 |
- Chromogenic factor VIII reagents. Assays with human coagulation factors respond to emicizumab and may overestimate its hemostatic potential. Assays with bovine factors are insensitive to emicizumab and measure endogenous or infused factor VIII and anti-factor VIII inhibitors (Hemlibra label 2025).
- Duration. Effects on coagulation assays may persist for up to 6 months after the last dose (Hemlibra label 2025).
- External quality assessment. In a UK NEQAS exercise, aPTT results were below the lower reference limit and unmodified one-stage factor VIII results were markedly high. A human-component chromogenic assay gave coefficients of variation of 38–40%. A modified OSA with emicizumab calibrators gave similar results with all aPTT reagents (Lowe 2020).
- Drug level. Emicizumab concentration is measured with an OSA modified by an emicizumab-specific calibrator and high plasma dilution (Bowyer 2023). Chromogenic factor VIII assays gave lower emicizumab concentrations than modified OSAs in one comparison (Gran 2025). An optimized two-stage chromogenic assay with heat inactivation of factor VIII had a lower limit of quantification of 2 µg/mL in manual format (Hamedani 2022).
- Heat treatment. Emicizumab survives heating, so heat treatment leaves it in the sample before inhibitor testing (Miller 2018).
- Acquired hemophilia A. In the United States, emicizumab is approved only for congenital hemophilia A with or without factor VIII inhibitors and is used off-label in acquired hemophilia A (Hemlibra label 2025; Lim 2026; Su 2026). Japan approved it for acquired hemophilia A in June 2022 after the AGEHA study (Shima 2026). The 2020 international recommendations advised against its use in acquired hemophilia A outside clinical trials because its safety and efficacy were then unknown (Tiede 2020). In treated patients, factor VIII activity and inhibitor titers are measured with bovine chromogenic assays (Hemlibra label 2025).
Laboratory monitoring of fitusiran and concizumab
| Agent | Mechanism | Laboratory monitoring | Source |
|---|---|---|---|
| Fitusiran | Antithrombin-directed small interfering RNA | AT activity measured with an FDA-cleared assay before initiation; not initiated if AT activity is <60%; AT activity measured at weeks 4, 12, 20 and 24 after the starting dose and after any dose change; dose adjusted to a target AT activity of 15–35%; annual AT activity once the target dose is found | Qfitlia label 2025 |
| Fitusiran safety threshold | Persistent AT activity <15% is associated with thrombotic events | Dose reduction for AT activity <15%; about 12 weeks allowed for AT recovery | Qfitlia label 2025 |
| Concizumab | Antibody against tissue factor pathway inhibitor | Loading dose 1 mg/kg on day 1, then 0.2 mg/kg daily; plasma concentration by an FDA-authorized concizumab ELISA 4 weeks after initiation, before the next dose; maintenance dose set no later than 8 weeks: <200 ng/mL, 0.25 mg/kg; 200–4,000 ng/mL, 0.2 mg/kg; >4,000 ng/mL, 0.15 mg/kg daily; a concentration above 200 ng/mL lowers bleeding risk | Alhemo label 2025 |
| Concizumab laboratory effects | Concentration correlates with D-dimer and prothrombin fragment 1+2 | Increased D-dimer and prothrombin fragment 1+2 | Alhemo label 2025 |
Factor XIII assays
- Screening tests. Delayed bleeding or bleeding out of proportion with normal PT, aPTT, thrombin time and fibrinogen raises suspicion of factor XIII deficiency (Jacobs 2026).
- Activity assays. Quantitative factor XIII activity is the recommended first-line test. Ammonia-release assays activate factor XIII with thrombin and calcium and measure released ammonia by a glutamate dehydrogenase reaction. A plasma blank avoids false signal from background ammonia (Jacobs 2026).
- Clot solubility tests. Solubility of clots in 5 M urea or 1% monochloroacetic acid detects only severe deficiency (about 1–5% activity). Hypofibrinogenemia and dysfibrinogenemia cause false positives, and the tests are not used as the sole diagnostic test (Jacobs 2026).
- Antigen assays. Factor XIII-A and factor XIII-B antigen assays separate F13A1 from F13B deficiency. Platelets contain factor XIII-A, so platelet-poor plasma (<10 × 10⁹/L platelets) avoids falsely high factor XIII-A antigen (Jacobs 2026).
- Ten-year laboratory series. Of 2,191 samples tested over 10 years, factor XIII activity was low in 14%. Urea clot solubility tests were largely noninformative, because all 7 abnormal samples had undetectable factor XIII-A antigen. Most deficiencies (92%) were acquired, mainly from consumption, major bleeding or severe infection (Al Sharif 2025).
Fibrinogen disorders and the activity-to-antigen ratio
Congenital fibrinogen disorders comprise afibrinogenemia and hypofibrinogenemia (quantitative) and dysfibrinogenemia and hypodysfibrinogenemia (qualitative) (Alotaibi 2026).
| Disorder | Laboratory definition | Source |
|---|---|---|
| Afibrinogenemia | Fibrinogen activity below the limit of detection and undetectable fibrinogen antigen | Alotaibi 2026 |
| Quantitative defect | Activity-to-antigen ratio ≥0.7 | Alotaibi 2026 |
| Qualitative or combined defect | Activity-to-antigen ratio <0.7 (some laboratories use 0.55) | Alotaibi 2026 |
Activity and antigen are measured in the same laboratory on the same specimen, and ratios near 0.7 are repeated (Alotaibi 2026). Clauss and PT-derived fibrinogen methods are described in Coagulation Specimen Collection, Screening Tests and Mixing Studies.
Rare factor and contact factor deficiencies
- Factor VII deficiency. In 422 patients from international registries, 61% had bleeding. Factor VII activity ≥19 IU/dL identified asymptomatic patients and <11 IU/dL identified grade III bleeding. Heterozygous patients were mostly asymptomatic (Mohsenian 2026).
- Prekallikrein deficiency. Its aPTT findings are described in Coagulation Specimen Collection, Screening Tests and Mixing Studies.
- Factor XI deficiency. Factor XI deficiency (hemophilia C) results from variants in F11, and severe deficiency is inherited as an autosomal recessive trait. Its prevalence is about 1 in 1,000 in people of Ashkenazi Jewish descent (Santacroce 2025).
- Factor XI activity and bleeding. A cohort study defined severe deficiency as factor XI activity below 20 IU/dL. In its 93 individuals from 39 families, mean activity was 39 IU/dL (range 18–79) in heterozygotes and 10.6 IU/dL (range 1–36) in homozygotes and compound heterozygotes. Bleeding occurred in 31%, and 54% of index cases were identified from abnormal preoperative or routine screening tests. Factor XI activity and F11 genotype did not reliably predict bleeding (Santacroce 2025).
Factor patterns in vitamin K deficiency, liver disease and amyloidosis
- Vitamin K-dependent proteins. Factors II, VII, IX and X, protein C and protein S are vitamin K dependent (Gorio 2025).
- Chronic liver disease. Hepatic synthesis of factors II, V, VII, IX, X and XI falls. Factor VIII, which is largely endothelial in origin, is preserved or elevated, and VWF is elevated (Agouba 2026). Rebalanced hemostasis in cirrhosis is described in DIC, Thrombotic Microangiopathy and Viscoelastic Testing.
- Factor V and factor VIII as discriminators. Factor V is synthesized in the liver and is not vitamin K dependent (Agouba 2026; Gorio 2025). A low factor V with preserved factor VIII therefore indicates impaired hepatic synthesis.
- PIVKA-II. Without vitamin K, undercarboxylated prothrombin (PIVKA-II, protein induced by vitamin K absence or antagonism) is released into plasma and is measured by immunoassay. The PT rises by 1–2 seconds only when carboxylated prothrombin falls below about 50%, while PIVKA-II rises about 20-fold when active prothrombin is still about 90%. PIVKA-II is therefore a sensitive marker of functional vitamin K insufficiency, including in newborns (Santorino 2015).
- Light chain (AL) amyloidosis. Factor X is adsorbed to amyloid fibrils. Of 368 patients with systemic AL amyloidosis, 32 (8.7%) had factor X below 50% of normal, and 18 of them bled. Bleeding was more frequent and severe below 25% (Choufani 2001). The American Society of Hematology (ASH) 2026 amyloidosis guideline lists easy bleeding and bruising from acquired factor X deficiency among clinical features (Kukreti 2026).
Von Willebrand Factor Testing and Platelet Function Testing
Definition. Von Willebrand factor (VWF) is a plasma protein that mediates platelet adhesion and stabilizes factor VIII (Nichols 2008). Von Willebrand disease (VWD) is caused by deficiency or dysfunction of VWF and is the most common inherited bleeding disorder. Its prevalence is estimated at up to 1% in the general population, with a symptomatic prevalence of about 1 in 1,000 (James 2021; Bowman 2025; Kalot 2021). Platelet function tests assess adhesion, aggregation and granule secretion. They are used to investigate inherited and acquired platelet function disorders and to monitor antiplatelet drugs (Burley 2026; Yoon 2024). The current diagnostic guideline for VWD is the American Society of Hematology (ASH), International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF) and World Federation of Hemophilia (WFH) 2021 guideline (James 2021). A 2025 review of literature published through July 2024 found no study that would change the direction or strength of any recommendation, and the 2021 guideline remains current (James 2025).
Related page: Coagulation Specimen Collection, Screening Tests and Mixing Studies (specimen handling and screening test patterns) Related page: Clotting Factor Assays, Factor Inhibitors and Interference by Hemophilia Therapies (factor VIII assays and the distinction from mild hemophilia A) Related page: DIC, Thrombotic Microangiopathy and Viscoelastic Testing (ADAMTS13 and viscoelastic testing) Related page: Hemolytic Disease of the Fetus and Newborn, Fetomaternal Hemorrhage, Rh Immune Globulin and Fetal and Neonatal Transfusion (fetal and neonatal alloimmune thrombocytopenia)
Von Willebrand factor structure and function in assay design
Circulating VWF is globular and does not bind platelets until it is activated. At sites of vascular injury, VWF binds subendothelial collagen and uncoils, exposing its A1 domain, which binds platelet glycoprotein Ib (GPIb) (Tosetto 2026). VWF and its propeptide (VWFpp) are secreted in equimolar amounts. The half-life of VWF is 8–12 hours and that of VWFpp is 2 hours (Tosetto 2026). VWF is an acute-phase reactant that rises with bleeding, trauma and pregnancy, so diagnostic testing is performed at a baseline state of health (James 2021). Specimen handling for VWF testing is described in Coagulation Specimen Collection, Screening Tests and Mixing Studies.
Von Willebrand factor assays
| Assay | Principle | Use | Source |
|---|---|---|---|
| VWF antigen (VWF:Ag) | Immunoassay of VWF protein | First-level panel | Tosetto 2026 |
| VWF ristocetin cofactor activity (VWF:RCo) | Ristocetin-induced agglutination of platelets by VWF | Platelet-binding activity; former reference method | Tosetto 2026 |
| VWF:GPIbR | Binding of ristocetin-activated VWF to recombinant wild-type GPIb | Platelet-binding activity | Tosetto 2026 |
| VWF:GPIbM | Spontaneous binding of VWF to a gain-of-function mutant GPIb fragment, without ristocetin | Platelet-binding activity | Tosetto 2026 |
| Factor VIII activity (FVIII:C) | Clot-based or chromogenic factor assay | First-level panel; FVIII:C/VWF:Ag ratio for type 2N | Tosetto 2026 |
| VWF collagen binding (VWF:CB) | ELISA or chemiluminescent binding to collagen type I and/or III | Surrogate for high-molecular-weight multimers | Tosetto 2026; James 2021 |
| VWF multimers | Electrophoresis of nonreduced plasma on agarose-SDS gels (1.4–2.0% medium and 0.7–1.2% low resolution) with western blot | Separates 2A and 2B from 2M | Tosetto 2026 |
| Ristocetin-induced platelet aggregation (RIPA) | Patient platelet-rich plasma with low and standard ristocetin concentrations | Agglutination at low concentration in type 2B and platelet-type VWD | Tosetto 2026 |
| VWF factor VIII binding (VWF:FVIIIB) | ELISA of factor VIII binding to captured VWF | Type 2N | Tosetto 2026; James 2021 |
| VWF propeptide (VWFpp) | ELISA | VWFpp/VWF:Ag ratio rises with increased clearance | Tosetto 2026 |
- First-level panel. Most guidelines, including the 2021 guideline, use VWF:Ag, a platelet-dependent VWF activity and FVIII:C (Tosetto 2026). VWD is excluded when all 3 are normal, usually at ≥50 IU/dL (Tosetto 2026).
- Choice of activity assay. The 2021 guideline suggests VWF:GPIbM or VWF:GPIbR over VWF:RCo, because the newer assays have lower coefficients of variation and higher reproducibility. These assays are performed in a laboratory with appropriate expertise (James 2021).
- The p.D1472H variant. It reduces ristocetin binding to the A1 domain and lowers VWF:RCo without affecting VWF function or bleeding risk. The 2021 panel cited this variant as a risk of overdiagnosis with VWF:RCo (James 2021). It is present in 67% of African American and 17% of White persons in the studies reviewed (Kalot 2022). VWF:GPIbM, which uses no ristocetin, is not affected (Tosetto 2026).
- Reference intervals. The local lower limit of normal is used when it is below 0.50 IU/mL. ABO-specific reference ranges are not required (James 2021).
Laboratory diagnosis of von Willebrand disease under the 2021 guideline
| Question | 2021 recommendation | Source |
|---|---|---|
| Type 1 cutoff | VWF <0.30 IU/mL regardless of bleeding, or <0.50 IU/mL with abnormal bleeding; VWF level means VWF:Ag and/or platelet-dependent activity | James 2021 |
| Type 2 ratio cutoff | Platelet-dependent VWF activity/VWF:Ag <0.7 | James 2021 |
| Type 2A, 2B or 2M classification | VWF multimer analysis or VWF:CB/VWF:Ag | James 2021 |
| Type 2B | Targeted genetic testing over low-dose RIPA | James 2021 |
| Type 2N | VWF:FVIIIB or targeted genetic testing | James 2021 |
| Type 1C (increased clearance) | Desmopressin trial with 1- and 4-hour samples, suggested over the VWFpp/VWF:Ag ratio | James 2021 |
| Activity assay | VWF:GPIbM or VWF:GPIbR over VWF:RCo | James 2021 |
| Levels normalized with age | Reconsideration of the diagnosis, suggested over its removal | James 2021 |
Previous rules. Earlier guidelines, including the 2008 National Heart, Lung, and Blood Institute (NHLBI) expert panel guideline, classified VWF <0.30 IU/mL as type 1 VWD and VWF 0.30–0.50 IU/mL as "low VWF" (Bowman 2025; Nichols 2008). Activity/antigen ratio cutoffs for type 2 VWD ranged from 0.5 to 0.7, and the 2021 guideline chose <0.7 over <0.5 (Bowman 2025). The 2021 guideline removed the "low VWF" category. This was its most debated recommendation (Bowman 2025).
- Desmopressin trial. Increased VWF clearance accounts for about 15–20% of type 1 VWD (James 2021). VWF levels are measured before and 1 and 4 hours after desmopressin. A good 1-hour rise followed by a rapid fall by 4 hours indicates increased clearance (type 1C) (James 2021; Tosetto 2026). The guideline evidence review found no agreed reference standard that defines type 1C (Kalot 2022).
- Ratio below 0.7 with normal levels. Some patients with type 2 VWD have normal VWF:Ag and activity and a low activity/antigen ratio (James 2021).
- Low-dose RIPA versus genetic testing. The pooled sensitivity was 1.00 for genetic testing and 0.99 for low-dose RIPA in diagnosing type 2B (James 2021).
Bleeding assessment tools in the evaluation for VWD
The 2021 guideline recommends a validated bleeding assessment tool (BAT) as the initial screen when the probability of VWD is low, as in primary care. It suggests against relying on a BAT to decide on blood testing when the probability is intermediate, as in referral to a hematologist (about 20% prevalence). It recommends against relying on a BAT when the probability is high, as with an affected first-degree relative (about 50%) (James 2021). The ISTH/SSC BAT is a standardized questionnaire with a bleeding score for inherited bleeding disorders (Rodeghiero 2010).
| Group | Normal ISTH-BAT score | Abnormal score | Source |
|---|---|---|---|
| Adult males | 0–3 | ≥4 | Elbatarny 2014; van Galen 2021 |
| Adult females | 0–5 | ≥6 | Elbatarny 2014; van Galen 2021 |
| Children | 0–2 | ≥3 | Elbatarny 2014; van Galen 2021 |
The normal ranges come from 1,040 adults and 328 children (Elbatarny 2014).
Laboratory classification of von Willebrand disease types
| Type | Defect | Laboratory pattern | Source |
|---|---|---|---|
| 1 | Partial quantitative deficiency; about 75% of VWD | Reduced VWF:Ag and platelet-dependent activity with an activity/antigen ratio ≥0.7; factor VIII normal or slightly reduced | Bowman 2025; James 2021; Castaman 2026 |
| 1C | Increased VWF clearance | High VWFpp/VWF:Ag ratio; good 1-hour response to desmopressin with a rapid fall by 4 hours | Castaman 2026; Tosetto 2026 |
| 2A | Absence or marked reduction of high- and intermediate-molecular-weight multimers, with reduced GPIb binding | Activity/antigen and VWF:CB/VWF:Ag <0.7; loss of large multimers | Castaman 2026; Tosetto 2026 |
| 2B | Increased affinity of VWF for GPIb | Agglutination at low ristocetin concentration; loss of large multimers; variable thrombocytopenia, worse with desmopressin or physiologic stress | Castaman 2026; Tosetto 2026 |
| 2M | Reduced or absent GPIb binding with intact multimers; rare collagen-binding variants | Activity/antigen <0.7 with normal VWF:CB/VWF:Ag and a full multimer range | Castaman 2026; Tosetto 2026 |
| 2N | Reduced binding of factor VIII, with shortened factor VIII half-life | FVIII:C/VWF:Ag <0.7; reduced VWF:FVIIIB | Castaman 2026; Tosetto 2026 |
| 3 | Virtual absence of VWF; about 5% of cases; autosomal recessive | VWF virtually absent; factor VIII usually <5 IU/dL | Castaman 2026 |
- Type 2N and hemophilia A. A FVIII:C/VWF:Ag ratio below 0.7 occurs in type 2N VWD and in mild hemophilia A. VWF:FVIIIB is reduced in type 2N and normal in hemophilia A (Tosetto 2026). Factor VIII assay methods are in Clotting Factor Assays, Factor Inhibitors and Interference by Hemophilia Therapies.
- Platelet-type VWD. Gain-of-function variants in platelet GP1BA increase binding between GPIbα and VWF. Inheritance is autosomal dominant (Seidizadeh 2025). Agglutination at low ristocetin concentrations can lead to misdiagnosis as type 2B (Tosetto 2026). Population genetic data estimate a global prevalence of 136 per million, which suggests underdiagnosis (Seidizadeh 2025).
Acquired von Willebrand syndrome
Acquired von Willebrand syndrome (AVWS) is a structural or functional VWF defect secondary to another disorder. The underlying disorders are lymphoproliferative, myeloproliferative, malignant, cardiovascular and autoimmune (Tiede 2011). The 3 mechanisms are antibody-mediated clearance or functional interference, adsorption to transformed cells or platelets, and proteolysis under increased shear stress (Tiede 2011). No single test proves or excludes AVWS (Tiede 2011). The workup measures VWF:Ag, VWF GPIb-binding activity and VWF:CB, preferably with multimer analysis. Bleeding is not required for the diagnosis (Zetterberg 2026).
| Setting | Laboratory findings | Source |
|---|---|---|
| Severe aortic stenosis | Reduced VWF:CB and loss of the largest multimers, abnormal high-shear platelet function, or both, in 67–92% of patients; correlated with stenosis severity; corrected on the first day after valve replacement; tended to recur at 6 months, especially with patient-prosthesis mismatch | Vincentelli 2003 |
| Continuous-flow left ventricular assist device | AVWS in all 102 patients tested; high-molecular-weight multimers reduced to 30 ± 14% (axial flow) and 34 ± 13% (centrifugal flow) | Meyer 2014 |
| Continuous-flow LVAD bleeding | Bleeding in 44.3% of 79 patients, most often gastrointestinal | Uriel 2010 |
| Extracorporeal membrane oxygenation | AVWS, platelet dysfunction and hemolysis contribute to bleeding; routine coagulation tests can miss these disorders | Mirus 2023 |
| Myeloproliferative neoplasms | Defined as VWF:GPIbM/VWF:Ag <0.65 in one cohort; present in 38% at diagnosis; associated with platelet counts >700 × 10⁹/L (odds ratio 10), polycythemia and female sex | Lemarié 2026 |
In the aortic stenosis series, skin or mucosal bleeding occurred in 21% of patients with severe stenosis (Vincentelli 2003). Bleeding with aortic stenosis is associated with an acquired type 2A pattern (Vincentelli 2003).
Platelet function analyzer closure time
The PFA-100 and PFA-200 aspirate whole blood through a cartridge membrane coated with collagen and another agonist under high shear. The closure time is the time to occlusion of the aperture by a platelet plug (Yoon 2024). The cartridges are collagen/epinephrine (COL/EPI) and collagen/adenosine diphosphate (COL/ADP) (Yu 2020).
- Drug effects. Aspirin and nonsteroidal anti-inflammatory drugs prolonged COL/EPI and did not affect COL/ADP in one series (Yu 2020).
- Variables affecting closure time. Blood group, hematocrit, platelet count and time of collection affect closure times (Yu 2020). A hematocrit below 30% or above 50% and a platelet count below 100 × 10⁹/L are listed as rejection criteria for the PFA (Magnette 2016).
- VWD screening. A prolonged closure time suggests VWD or a platelet defect. A normal closure time does not exclude mild VWD (Tosetto 2026). The PFA is sensitive to many hemostatic disturbances and specific for none (Favaloro 2008).
- Inherited platelet function disorders. The 2015 ISTH guidance did not recommend the PFA or the bleeding time for these disorders because of inadequate sensitivity, specificity and reproducibility (Burley 2026). The bleeding time is considered obsolete (Tosetto 2026).
Light transmission aggregometry and platelet secretion assays
Light transmission aggregometry (LTA) in platelet-rich plasma (PRP) is the reference method for platelet aggregation (Burley 2026). An ISTH SSC working party issued consensus recommendations on LTA, covering preanalytical variables, blood processing, choice of agonists and reporting, by the RAND method (Cattaneo 2013).
- PRP preparation. PRP is prepared by centrifugation at 200–250 g for 10 minutes without the brake (Magnette 2016).
- Timing. Samples are kept at room temperature for at least 15 minutes, and testing is completed within 3–4 hours of collection (Magnette 2016).
- Platelet count. Dilution of PRP with autologous platelet-poor plasma to standardize the count can reduce responses to weak agonists. Thrombocytopenia or low PRP counts impair aggregation independently of platelet function (Burley 2026).
| Agonist | Typical concentration (BSH initial panel) | Pathway tested | Source |
|---|---|---|---|
| ADP | 5 and 10 µM | P2Y1 and P2Y12 | Burley 2026 |
| Collagen (type I) | 1 or 1.25 µg/mL | GPVI and integrin α2β1 | Burley 2026 |
| Epinephrine | 5 and 10 µM | α2-adrenergic receptor; depends on secretion | Burley 2026 |
| Arachidonic acid | 1 mM | Cyclooxygenase-1 and thromboxane A2 generation | Burley 2026 |
| Ristocetin | 0.5 g/L (low) and 1.25 g/L (standard) | VWF–GPIb-IX-V interaction | Burley 2026 |
| TRAP-6 (extended panel) | 5 and 10 µM | PAR1 thrombin receptor | Burley 2026 |
| U46619 (extended panel) | 1 µM | Thromboxane receptor, bypassing cyclooxygenase-1 | Burley 2026 |
- Secretion assays. ISTH SSC experts agreed that platelet secretion assays are first-line tests even when aggregation is normal and include a dense granule marker. Lumiaggregometry was rated appropriate for dense granule release, and P-selectin by flow cytometry for α-granule release (Mezzano 2022).
- Dense granule assays. Measurement of ADP and ATP content identifies δ-storage pool deficiency. Lumiaggregometry measures agonist-induced ATP release and detects release defects (Burley 2026).
- Whole blood impedance aggregometry. Impedance aggregometry measures the change in electrical resistance across electrodes as platelets aggregate in whole blood (Yoon 2024). In a pediatric cohort, whole blood impedance lumiaggregometry had a sensitivity of 91.1% and specificity of 87.2%, and LTA 92.4% and 84.5% (Doshi 2026).
Flow cytometry for platelet glycoproteins
Flow cytometry of resting platelets for GPIIb/IIIa (CD41/CD61), GPIb (CD42b) and GPIb/IX (CD42a), and of activated platelets for the GPIIb/IIIa activation epitope (PAC-1), is a first-step test for suspected inherited platelet function disorders. It identifies mainly Glanzmann thrombasthenia and Bernard-Soulier syndrome (Burley 2026). Citrate is the preferred anticoagulant for many platelet flow cytometry tests (Frelinger 2021). Next-generation sequencing gene panels are the preferred strategy when laboratory testing does not discriminate (Burley 2026).
Laboratory patterns of inherited platelet function disorders
| Disorder | Gene(s) | Laboratory findings | Source |
|---|---|---|---|
| Glanzmann thrombasthenia | ITGA2B, ITGB3 (autosomal recessive) | Absent or reduced response to all agonists except ristocetin | Safdari 2025 |
| Bernard-Soulier syndrome | GP1BA, GP1BB, GP9 (autosomal recessive) | Giant platelets; absent or reduced response to ristocetin with normal response to other agonists | Safdari 2025 |
| Aspirin-like defect | Cyclooxygenase-1 or thromboxane pathway | Reduced response to arachidonic acid; U46619 separates synthesis defects from receptor defects | Burley 2026 |
| δ-storage pool deficiency | Dense granule defect | Reduced ADP and ATP content; reduced secretion | Burley 2026 |
| Gray platelet syndrome | NBEAL2 (predominantly recessive) | Mild thrombocytopenia with large platelets; paucity of α-granules | Albers 2011 |
| Platelet-type VWD | GP1BA gain of function (autosomal dominant) | Agglutination at low ristocetin concentration | Seidizadeh 2025; Tosetto 2026 |
- Pediatric distribution. Among 137 children with platelet function disorders, nonspecific defects (57.7%) and storage pool disorders (21.2%) were most common. Bernard-Soulier syndrome and Glanzmann thrombasthenia were rare (Doshi 2026).
- Survey of practice. In a 2014 survey of 202 laboratories, 40% of about 14,000 patients investigated each year had a platelet function defect, and 8.7% of these received a molecular diagnosis (Burley 2026).
- ISTH-BAT in platelet disorders. Once VWD was excluded, scores above 4 in women and above 3 in men separated patients with platelet function disorders from controls (Burley 2026). These disorder-specific cutoffs differ from the abnormal scores in the general population (≥4 in adult males, ≥6 in adult females, ≥3 in children; Elbatarny 2014).
Acquired platelet dysfunction and antiplatelet drug monitoring
- Exclusion of acquired causes. Drugs, food supplements, renal failure and myeloid malignancy are excluded before an inherited platelet function disorder is diagnosed (Burley 2026).
- VerifyNow. The VerifyNow system measures light transmittance in whole blood as platelets aggregate on fibrinogen-coated beads with cartridge-specific agonists. It is used to monitor antiplatelet therapy, and hematocrit and platelet count limit its range (Yoon 2024).
- Clinical use of testing. American and European guidelines give a class IIb recommendation for platelet function testing to guide P2Y12 inhibitor choice in selected high-risk patients after percutaneous coronary intervention and a class III recommendation against routine testing (Tantry 2013). Low on-treatment platelet reactivity is associated with bleeding, which led to the therapeutic window concept for P2Y12 inhibitors (Tantry 2013).
- Uremia. Uremic toxins interfere with platelet membrane receptors, reduce intracellular calcium mobilization and impair granule secretion. Adhesion, aggregation and secretion are defective even when the platelet count is normal (Altahan 2025). Nitric oxide and prostacyclin levels are elevated in uremia and further inhibit platelet function. Clinical findings are a prolonged bleeding time, easy bruising and mucosal bleeding (Badulescu 2025). Erythropoietin improves the bleeding time without restoring platelet activation. Desmopressin and dialysis improve uremic bleeding (Altahan 2025).
Thrombophilia Testing and Antiphospholipid Antibody Testing
Definition. Thrombophilia is a heritable or acquired condition that increases the predisposition to thrombosis. The best-defined heritable thrombophilias are the factor V Leiden variant (F5 G1691A), the prothrombin gene variant (F2 G20210A) and deficiencies of protein C, protein S and antithrombin. The main acquired thrombophilias are the antiphospholipid syndrome (APS), paroxysmal nocturnal hemoglobinuria (PNH), myeloproliferative neoplasms (MPN) and a JAK2 variant without an MPN phenotype (Arachchillage 2022). A thrombophilia panel usually contains assays for antithrombin, protein C and protein S, genotyping for factor V Leiden and the prothrombin variant, and the three laboratory criteria of APS: lupus anticoagulant (LA), anticardiolipin antibodies (aCL) and anti-β2-glycoprotein I antibodies (anti-β2GPI) (Middeldorp 2023).
Related page: Coagulation Specimen Collection, Screening Tests and Mixing Studies (citrate specimens, mixing studies and screening-test patterns) Related page: Anticoagulant Monitoring, DOAC Measurement and Heparin-Induced Thrombocytopenia Testing (anti-Xa methods and drug-specific DOAC assays) Related page: Clotting Factor Assays, Factor Inhibitors and Interference by Hemophilia Therapies (one-stage and chromogenic factor assays)
Indications for thrombophilia testing in the ASH 2023 guideline
The American Society of Hematology (ASH) 2023 guideline on thrombophilia testing is part of the ASH guidelines for management of venous thromboembolism. Its panel issued 23 recommendations. Nearly all rest on very low certainty evidence derived from modeling (Middeldorp 2023).
| Clinical scenario | ASH 2023 recommendation | Source |
|---|---|---|
| Unprovoked VTE after primary treatment | No testing to guide duration (conditional) | Middeldorp 2023 |
| VTE provoked by surgery | No testing (conditional) | Middeldorp 2023 |
| VTE provoked by a nonsurgical major transient risk factor | Testing; indefinite anticoagulation if thrombophilia is found (conditional) | Middeldorp 2023 |
| VTE provoked by pregnancy or the postpartum period | Testing (conditional) | Middeldorp 2023 |
| VTE associated with combined oral contraceptives (COCs) | Testing (conditional) | Middeldorp 2023 |
| VTE of unspecified type | No testing (conditional) | Middeldorp 2023 |
| Cerebral or splanchnic venous thrombosis where anticoagulation would otherwise stop | Testing (conditional) | Middeldorp 2023 |
| Cerebral or splanchnic venous thrombosis where anticoagulation would continue indefinitely | No testing (conditional) | Middeldorp 2023 |
| Individual with a family history of VTE and known familial factor V Leiden or prothrombin variant, facing a minor provoking factor | No testing for the familial variant (conditional) | Middeldorp 2023 |
| Individual with a family history of VTE and known familial antithrombin, protein C or protein S deficiency, facing a minor provoking factor | Testing for the familial defect; thromboprophylaxis if present (conditional) | Middeldorp 2023 |
| General population before COCs | No testing (strong) | Middeldorp 2023 |
- Previous position. The ASH Choosing Wisely list of 2013 advised against thrombophilia testing in adults with VTE in the setting of transient major risk factors (Hicks 2013).
- Tests outside the panel. ASH 2023 gives no guidance on methylenetetrahydrofolate reductase (MTHFR) polymorphisms, which are not associated with VTE. It also gives no guidance on factor VIII, factor IX and factor XI activity, plasminogen activator inhibitor type 1 (PAI-1) and the PAI-1 4G/5G polymorphism, which are not conclusively associated with VTE (Middeldorp 2023).
BSH 2022 recommendations on thrombophilia testing
The British Society for Haematology (BSH) 2022 guideline updated and widened the earlier BSH guideline on heritable thrombophilia (Arachchillage 2022).
- After VTE. Testing for heritable traits is not recommended as a routine to guide management (grade 2B). Routine testing of first-degree relatives is not recommended (grade 2B). Selective testing of asymptomatic first-degree relatives of probands with protein C, protein S or antithrombin deficiency is suggested when it may influence management (grade 2B) (Arachchillage 2022).
- Antiphospholipid antibodies after VTE. Screening is recommended after unprovoked VTE (grade 1B) and suggested after VTE provoked by a minor risk factor (grade 2C). Screening of family members is not recommended, because APS is acquired (grade 1A) (Arachchillage 2022).
- Unusual sites. Heritable thrombophilia testing is not recommended when the only indication is thrombosis at an unusual site (grade 2B). Antiphospholipid antibody testing is recommended for unprovoked thrombosis at unusual sites (grade 1A) (Arachchillage 2022).
- Arterial thrombosis and stroke. Heritable thrombophilia testing is not recommended in arterial thrombosis (grade 1B) or stroke at any age (grade 1A). Antiphospholipid antibody testing is recommended in arterial thrombosis without other vascular risk factors (grade 1B) and considered in stroke before age 50 years without cardiovascular risk factors (grade 1A) (Arachchillage 2022).
- Children. Neonates and children with purpura fulminans are tested urgently for protein C and protein S deficiency (grade 1B) (Arachchillage 2022).
- Pregnancy complications. Heritable thrombophilia screening is not recommended after recurrent miscarriage or adverse pregnancy outcomes (grade 2B). Antiphospholipid antibody screening can be considered after recurrent or late pregnancy loss (grade 2B) (Arachchillage 2022).
- Gene variants without a clinical link. Testing for MTHFR and SERPINE1 variants is not recommended (grade 2C) (Arachchillage 2022).
Timing of thrombophilia testing and interference by anticoagulants
- Natural anticoagulants. Testing for antithrombin, protein C and protein S deficiency is performed only after 3 months of anticoagulation for acute thrombosis (grade 2B). Earlier results are of uncertain validity and do not influence acute management (Arachchillage 2022).
- Vitamin K antagonists. Warfarin lowers protein C activity and free protein S antigen (Arachchillage 2022). Protein C deficiency may be acquired from vitamin K antagonist treatment or liver disease (Cooper 2020).
- Direct oral anticoagulants (DOACs). Direct factor Xa inhibitors affect factor Xa-based assays, and dabigatran affects thrombin (factor IIa)-based assays. Antigenic and chromogenic protein C and protein S assays showed no DOAC effect (Siriez 2021). Clot-based thrombophilia assays can give false-positive or false-negative results with any DOAC (Siriez 2021).
- Sampling at trough. A DOAC-free interval of at least 2 days, or sampling at trough concentration, is recommended before thrombophilia testing (cited in Favresse 2018).
DOAC removal devices
Activated-charcoal adsorbents remove DOACs from citrated plasma in vitro.
| Study | Finding | Source |
|---|---|---|
| DOAC-Stop in spiked and patient plasmas | Removed dabigatran, apixaban, rivaroxaban and edoxaban with minimal effect on PT/INR, LA, APC resistance, antithrombin, plasminogen, protein C and protein S tests | Exner 2018 |
| DOAC-Stop in 135 DOAC-treated patients | False-positive LA results occurred with all four DOACs before treatment; the dRVVT screen was affected more than the LA-sensitive aPTT and the dRVVT ratio | Favresse 2018 |
| DOAC-Stop and APC resistance | The APC resistance ratio fell after adsorption in dabigatran-treated patients (6.6 to 4.6) | Favresse 2018 |
| DOAC-Remove and Taipan snake venom time in 284 samples on factor Xa inhibitors | 90% agreement for LA detection, Cohen κ 0.12 | White 2022 |
Antithrombin assays
Hereditary antithrombin deficiency causes a high risk of VTE. Heterozygous deficiency raises the risk of a first VTE about 15-fold (Arachchillage 2022).
- Testing sequence. An activity assay is the initial test. An antigen assay and the activity-to-antigen ratio follow when activity is low (Van Cott 2020).
- Age. Pediatric reference ranges apply until 6 months of age (Van Cott 2020).
- Acquired decreases. Liver dysfunction, proteinuria, heparin, disseminated intravascular coagulation (DIC), thrombosis and surgery lower antithrombin (Van Cott 2020). The BSH lists late pregnancy, the early postpartum period, nephrotic syndrome, severe sepsis and L-asparaginase therapy as further causes (Arachchillage 2022).
- False normal or high results. Argatroban, bivalirudin and dabigatran raise results of factor IIa-based assays. Rivaroxaban, apixaban and edoxaban raise results of factor Xa-based assays; betrixaban does not (Van Cott 2020).
- Molecular testing. Molecular testing identifies variants missed by activity assays and may refine the thrombotic risk, which varies among variants (Van Cott 2020).
- Type I and type II defects. The risk of VTE is similar for type I and type II defects. Most type II heparin-binding-site defects carry about a 4-fold lower risk. Homozygous heparin-binding-site defects carry a high risk (Arachchillage 2022).
- Heparin response. Antithrombin testing is required when heparin resistance is present (Arachchillage 2022). Antithrombin assays in heparin monitoring are covered in Anticoagulant Monitoring, DOAC Measurement and Heparin-Induced Thrombocytopenia Testing.
Protein C and protein S assays
Heterozygous protein C or protein S deficiency raises the risk of a first VTE about 5–7-fold. Each deficiency has a population prevalence below 0.5% in people of European origin (Arachchillage 2022).
- Protein C method. The chromogenic protein C assay is recommended for its specificity. It fails to detect the rare type 2b deficiency, in which the defect lies in interaction with calcium ions, phospholipid, protein S and factors Va and VIIIa. The clot-based assay detects type 2b deficiency with lower specificity (Cooper 2020).
- Protein C preanalytical effects. A partially clotted sample gives a falsely raised chromogenic protein C level and a falsely reduced clot-based level. DOACs falsely raise protein C in the clot-based assay and leave the chromogenic assay unaffected (Cooper 2020).
- Protein C and age. Adult reference ranges are not applied to babies or children, and levels may remain below adult values in adolescence (Cooper 2020).
- Homozygous deficiency. Homozygous or compound heterozygous protein C deficiency is rare and serious, and affected infants often come from families with no history of thrombosis (Cooper 2020).
- Protein S biochemistry. About 60% of plasma protein S is bound to C4b-binding protein (C4bBP). Free protein S is the predominant active form (Nakashima 2014).
- Protein S deficiency types. Types I and III are quantitative deficiencies with low free protein S antigen and low activity, and together account for 95% of cases. Type I shows low total protein S antigen, and type III shows normal total protein S antigen. Type II is a qualitative defect with low activity and normal free and total antigen (Nakashima 2014).
- Protein S assays. Clot-based activity assays detect all types but are not specific. APC resistance, usually from factor V Leiden, and lupus anticoagulants interfere with them. An antigenic assay used as the initial test may miss type II deficiency (Nakashima 2014). Free protein S antigen is the protein S assay listed in the BSH guideline (Arachchillage 2022).
- Acquired protein S decrease. C4bBP is an acute-phase reactant, and its increase in the acute-phase response lowers protein S activity and free antigen. Factor VIII above 250% also lowers protein S (Nakashima 2014).
| Influence | Protein C activity (chromogenic) | Free protein S antigen | Antithrombin activity (chromogenic) |
|---|---|---|---|
| Physiologic reduction | Neonates and children | Neonates; pregnancy and puerperium | Neonates; late pregnancy and early postpartum |
| Other causes of reduction | Vitamin K antagonists, vitamin K deficiency, liver disease, DIC, severe sepsis | Vitamin K antagonists, vitamin K deficiency, liver disease, nephrotic syndrome, DIC, severe sepsis, recent thrombosis, oral estrogen, acute-phase response, sickle cell disease | Liver disease, DIC, nephrotic syndrome, severe sepsis, recent thrombosis, heparin, L-asparaginase |
| Artifactual increase | DOACs or heparin in a clot-based assay | DOACs or heparin in a clot-based assay | Factor Xa inhibitors in a factor Xa-based assay; thrombin inhibitors in a thrombin-based assay |
| Artifactual decrease | Factor V Leiden in a clot-based assay | Factor V Leiden in a clot-based assay | None listed |
Source: Arachchillage 2022 (Table 1).
Factor V Leiden and activated protein C resistance testing
- Molecular basis. Resistance to activated protein C (APC) was described in 1993 (Dahlbäck 1993). It is associated with a single point mutation in the factor V gene at nucleotide 1691 (G→A), which produces factor V Q506 (factor V Leiden), a molecule not properly inactivated by APC. The allele frequency in the Dutch population is about 2% (Bertina 1994).
- Frequency and risk. About 5% of people of European descent are heterozygous. The variant is rare or absent in sub-Saharan Africa, East Asia and the Indigenous populations of the Americas and Australia. Heterozygosity raises the relative risk of a first venous thrombosis about 5-fold (Arachchillage 2022).
- Detection. Factor V Leiden is detected with APC resistance assays, followed or replaced by molecular confirmation (Van Laer 2026). Genotyping uses polymerase chain reaction (PCR)-based methods (Arachchillage 2022).
- First-generation APC resistance assay. The aPTT of patient plasma is measured with and without added APC, and the ratio is compared with normal plasma. The ratio is 2.0 or more in normal individuals, 1.5–2.0 in factor V Leiden heterozygotes and below 1.5 in homozygotes. Each laboratory determines its own cut-off (Nakashima 2014).
- Interferences in the first-generation assay. Elevated factor VIII, protein S below 20% and causes of a prolonged baseline aPTT (heparin, warfarin, direct thrombin inhibitors, lupus anticoagulant, liver dysfunction) falsely lower the ratio (Nakashima 2014).
- Second-generation APC resistance assay. Patient plasma is diluted in factor V-deficient plasma containing a heparin neutralizer. This assay has higher sensitivity and specificity and is less affected by thrombosis, surgery, inflammation, heparin and warfarin (Nakashima 2014).
- APC resistance methods and DOACs. APC resistance methods based on the aPTT with factor V-deficient plasma are affected by all DOACs. A prothrombinase-based APC resistance method was unaffected by rivaroxaban (Favresse 2018).
Prothrombin G20210A variant
- Variant. A G→A transition at nucleotide 20210 in the 3′ untranslated region of the prothrombin gene was found in 18% of probands with familial thrombophilia and 1% of controls (Poort 1996).
- Plasma prothrombin. Of carriers of the 20210 A allele, 87% have plasma prothrombin in the highest quartile (>1.15 U/mL). The allele raised the risk of venous thrombosis almost 3-fold (odds ratio 2.8) (Poort 1996).
- Frequency. Heterozygosity is present in 1%–2% of Europeans and is rare or absent in other populations (Arachchillage 2022).
- Detection. The variant can be detected only by genetic testing (Van Laer 2026).
Elevated factor VIII, homocysteine and MTHFR
- Factor VIII. In a population-based case-control study, factor VIII above 1500 IU/L gave an adjusted odds ratio of 4.8 for deep vein thrombosis. Factor VIII mediated the effect of von Willebrand factor (VWF) and partly the effect of blood group (Koster 1995). In the MEGA study, factor VIII above the 95th centile gave an odds ratio of 16.0 after correction for age, sex and other coagulation factors (Arachchillage 2022).
- Factor VIII testing. Routine factor VIII testing is not recommended because of acquired influences, variation over time and lack of evidence that it changes management (Arachchillage 2022).
- MTHFR. Meta-analyses disproved an association between MTHFR polymorphism status and VTE (Hickey 2013). MTHFR variants and homocysteine levels are excluded from pediatric thrombophilia panels (Arachchillage 2022).
Lupus anticoagulant testing in the ISTH 2020 guidance
LA is detected with clot-based assays in three steps: screening, mixing and confirmation (Devreese 2020).
| Element | ISTH SSC 2020 | Previous rule, ISTH SSC 2009 | Source |
|---|---|---|---|
| Test systems | Two test systems, dRVVT and aPTT; three-step procedure essentially unchanged | Choice limited to dRVVT and a sensitive aPTT | Devreese 2020; Pengo 2009 |
| Mixing and confirmation | Performed simultaneously in each sample with a prolonged screening test; confirmation may be performed on a patient-pooled normal plasma mixture | Cut-off calculation stated for each diagnostic step | Devreese 2020; Pengo 2009 |
| Preanalytical phase | More detailed recommendations on anticoagulated patients and on timing; routine coagulation tests, and anti-Xa or DOAC-specific assays when necessary | Blood collection and processing delineated | Devreese 2020; Pengo 2009 |
| Patient selection | Expanded | New paragraph to minimize inappropriate requests | Devreese 2020; Pengo 2009 |
| Reporting | Unchanged, with more attention to what clinicians need to know | Interpretation in general and in particular situations | Devreese 2020; Pengo 2009 |
- Additions in 2020. Silica is the preferred aPTT activator, and ellagic acid is not excluded. Cut-offs are established in-house on at least 120 normal donors, with transference of manufacturer cut-offs as an alternative (Devreese 2020).
- Ratios. LA tests are interpreted as ratios of patient to normal pooled plasma clotting times. A normalized screen-to-confirm ratio above 1.30 is reported as positive, 1.20–1.30 as doubtful and below 1.20 as negative. Each laboratory implements its own diagnostic algorithm (Marco-Rico 2025).
- Mixing test. The index of circulating anticoagulant (ICA, Rosner index) = [(1:1 mix − normal pooled plasma)/patient screen] × 100, and a value above 12% suggests LA. The mixing-test-specific cut-off, expressed as a normalized ratio and ideally set at the 99th percentile of 120 healthy donors, is more sensitive than the ICA and is the ISTH-recommended method (Marco-Rico 2025).
- Confirmatory step. Percent correction = [(screen − confirm)/screen] × 100. A value above the cut-off suggests LA (Marco-Rico 2025).
- Timing of LA testing. LA is not tested in the acute thrombotic phase or during infection, surgery or cancer, when acute-phase reactants and factor VIII rise. C-reactive protein binds reagent phospholipid and causes false-positive results, and high factor VIII shortens the aPTT and causes false-negative results. LA testing is also avoided in pregnancy (Marco-Rico 2025).
Lupus anticoagulant testing in anticoagulated patients
| Anticoagulant | Effect on LA testing | Source |
|---|---|---|
| Unfractionated heparin and LMWH | Some reagents contain heparin neutralizers effective up to 1.0 U/mL; LA tests are less affected by LMWH | Tripodi 2020 |
| Vitamin K antagonists | May affect LA detection; dilution of test plasma in pooled normal plasma is unreliable and gives false-negative or false-positive results | Tripodi 2020 |
| DOACs | Affect LA detection; LA testing is not recommended during DOAC therapy; DOAC adsorbents were described as promising | Tripodi 2020 |
| Taipan snake venom time with ecarin time | Prothrombin activators insensitive to vitamin K antagonists and direct factor Xa inhibitors; interfered with by direct thrombin inhibitors, UFH and LMWH; independent evidence and standardized kits are still needed | Moore 2021; Tripodi 2020 |
- Taipan snake venom time validation. In a six-center study, cut-offs were 1.08–1.10 for the screening ratio and 1.09–1.12 for the ecarin confirmatory ratio. Sensitivity and specificity were 78.2% and 95.0% against established APS, and 86.9% and 95.0% against triple-positive APS (Moore 2021).
Antiphospholipid antibody testing in the ISTH-SSC 2025 update
- Core tests. LA, aCL and anti-β2GPI remain the core tests for the laboratory diagnosis of APS (Devreese 2025).
- Laboratory tests kept in the 2023 criteria. The 2023 classification criteria left the type of laboratory test essentially unchanged from the updated Sapporo criteria. aCL and anti-β2GPI are still restricted to ELISA, with moderate and high thresholds of 40 and 80 units, and the 99th-percentile cut-off has been abandoned (Devreese 2025).
- Topics of the 2025 update. The 2025 update addresses measurement by methods other than enzyme-linked immunosorbent assay (ELISA), semiquantitative titer reporting, the role of IgM and IgA, and antiphosphatidylserine/prothrombin (aPS/PT) antibodies (Devreese 2025).
- Solid-phase harmonization. The ISTH SSC and the APS ACTION network published a joint communication on harmonizing ELISA and non-ELISA aPL tests for the 2023 solid-phase domain, with a 2026 erratum (Meroni 2025; Meroni 2026).
APS classification: 2023 ACR/EULAR criteria and the Sydney 2006 criteria
Classification criteria are designed for research and are not diagnostic criteria (Devreese 2025; Alijotas-Reig 2025). The Sydney criteria of 2006 amended the 1999 Sapporo criteria and remained in use until 2023 (Miyakis 2006; Alijotas-Reig 2025).
- Entry criterion. At least one positive aPL test within 3 years of identification of an aPL-associated clinical criterion (Barbhaiya 2023).
- Structure. Additive weighted criteria (1–7 points each) in six clinical domains and two laboratory domains. Classification requires at least 3 points from clinical domains and at least 3 points from laboratory domains (Barbhaiya 2023).
- Performance. In the validation cohort, specificity was 99% for the 2023 criteria and 86% for the Sydney criteria. Sensitivity was 84% for the 2023 criteria and 99% for the Sydney criteria (Barbhaiya 2023).
| Laboratory domain | Finding | Points | Source |
|---|---|---|---|
| Domain 7: LA by functional coagulation assays | Positive on a single occasion | 1 | Alijotas-Reig 2025 |
| Domain 7 | Persistently positive | 5 | Alijotas-Reig 2025 |
| Domain 8: aCL and anti-β2GPI by ELISA | Moderate or high positive IgM aCL and/or anti-β2GPI | 1 | Alijotas-Reig 2025 |
| Domain 8 | Moderate positive IgG aCL and/or anti-β2GPI | 4 | Alijotas-Reig 2025 |
| Domain 8 | High positive IgG aCL or anti-β2GPI | 5 | Alijotas-Reig 2025 |
| Domain 8 | High positive IgG aCL and anti-β2GPI | 7 | Alijotas-Reig 2025 |
| Laboratory criterion | 2023 ACR/EULAR | Previous rule, Sydney 2006 | Source |
|---|---|---|---|
| Solid-phase method | ELISA only | ELISA | Devreese 2025; Alijotas-Reig 2025; Baltaci 2026 |
| aCL and anti-β2GPI threshold | Moderate 40–79 units, high ≥80 units; 99th-percentile cut-off abandoned | Medium or high titer IgG or IgM | Devreese 2025; Sheng 2026; Baltaci 2026 |
| IgM isotype | Scores 1 point and cannot reach the laboratory threshold alone | IgG or IgM qualifies | Sheng 2026 |
| Single positive LA | 1 point | Does not qualify; persistence on two occasions at least 12 weeks apart required | Alijotas-Reig 2025; Sheng 2026; Baltaci 2026 |
| Persistence | LA: single positive 1 point, persistent 5 points; aCL and anti-β2GPI scored only when persistently moderate or high positive | LA, aCL or anti-β2GPI positive on two or more occasions at least 12 weeks apart | Alijotas-Reig 2025; Sheng 2026; Baltaci 2026 |
- Antibodies without points. IgA and non-criteria antibodies receive no points (Sheng 2026).
Antiphospholipid antibody profiles and the timing of aPL testing
- Risk by profile. A positive LA is most strongly associated with recurrent thrombosis. Triple-positive individuals (LA, aCL and anti-β2GPI) have the highest thrombotic risk (Arachchillage 2022).
- Triple-positive carriers. Among 104 asymptomatic triple-positive carriers followed for a mean of 4.5 years, first thromboembolic events occurred at 5.3% per year, with a cumulative incidence of 37.1% at 10 years (Pengo 2011). Single-antibody carriers had a first-thrombosis incidence of about 1% per year, and women with obstetric APS about 0.5% per year (Arachchillage 2022).
- Pregnancy. aPL testing is avoided during pregnancy because results may be unreliable (grade 2B). Testing is performed at least 6 weeks after the end of pregnancy and repeated 12 weeks after the first test to confirm a positive result (Arachchillage 2022).
- Catastrophic APS. Patients with acute multiple thrombotic events and organ failure suggestive of catastrophic APS are tested for aPL (grade 1A) (Arachchillage 2022).
Thrombophilia in arterial thrombosis
- Acquired thrombophilia. APS, PNH and MPN increase the risk of both venous and arterial thrombosis. Arterial events account for 60%–70% of thrombotic events in MPN (Arachchillage 2022).
Testing for MPN and PNH in unusual-site thrombosis
- MPN panel. Testing for JAK2 V617F, JAK2 exon 12, CALR and MPL variants is recommended in thrombosis at unusual sites with blood count abnormalities suggesting an MPN (grade 1C). JAK2 testing is suggested in unprovoked splanchnic vein thrombosis or cerebral venous sinus thrombosis with a normal blood count (grade 2C) (Arachchillage 2022).
- JAK2 frequency. Isolated JAK2 variants occur in 0.1%–0.2% of the general population and in 2.9%–5.6% of patients with cerebral venous sinus thrombosis without an MPN phenotype. Peripheral blood testing is sensitive, and marrow samples are not required (Arachchillage 2022).
- PNH. PNH testing by flow cytometry for glycosylphosphatidylinositol-anchored proteins is suggested in thrombosis at unusual sites with cytopenia, abnormal red cell indices or hemolysis (grade 2C). Patients with a neutrophil clone above 50% have a 10-year thrombosis incidence of 34.5% (Arachchillage 2022).
Anticoagulant Monitoring, DOAC Measurement and Heparin-Induced Thrombocytopenia Testing
Definition. Anticoagulant monitoring is the laboratory measurement of the effect or concentration of an anticoagulant drug. The main methods are the activated partial thromboplastin time (aPTT), the anti-factor Xa (anti-Xa) assay, the activated clotting time (ACT), the international normalized ratio (INR) and drug-calibrated assays for direct oral anticoagulants (DOACs) (Reardon 2026; Douxfils 2018). Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction mediated by platelet-activating antibodies against complexes of platelet factor 4 (PF4) and heparin, with a markedly increased risk of thromboembolism (Cuker 2018).
Related page: Coagulation Specimen Collection, Screening Tests and Mixing Studies (specimen collection, PT/INR and aPTT principles) Related page: Thrombophilia Testing and Antiphospholipid Antibody Testing (DOAC effects on thrombophilia and lupus anticoagulant assays) Related page: DIC, Thrombotic Microangiopathy and Viscoelastic Testing (viscoelastic testing and thrombin generation) Related page: Transfusion Indications, Massive Transfusion, Platelet Refractoriness and Patient Blood Management (4F-PCC and vitamin K for warfarin reversal)
Unfractionated heparin monitoring by aPTT
- Calibration of the aPTT range. Reagent and analyzer variability requires local calibration of the aPTT therapeutic range against an anti-Xa range of about 0.3–0.7 IU/mL (Reardon 2026).
- Ratio. An aPTT ratio of 2.0–3.5 times the laboratory control is often associated with therapeutic unfractionated heparin (UFH). The historical range was 1.5–2.5 times control (Reardon 2026).
- Calibration method. Plasma samples from patients receiving UFH, preferably with a normal PT, are tested by aPTT and anti-Xa. Regression analysis interpolates the aPTT range from the anti-Xa range of 0.3–0.7 IU/mL (Reardon 2026).
- Preanalytical and patient factors. Heparin contamination and poor sample collection affect the aPTT. Inflammation, high fibrinogen and high factor VIII shorten it, and a lupus anticoagulant prolongs it independently of heparin (Reardon 2026).
- Preference for anti-Xa. Anti-Xa monitoring is preferred when the baseline aPTT is abnormal, for example from a lupus anticoagulant or a deficiency of factor VIII, IX, XI or XII, and when the aPTT does not respond to heparin (Reardon 2026).
Discordance between aPTT and anti-Xa
- Frequency. In patients on mechanical circulatory support receiving UFH, aPTT and anti-Xa results were concordant 35.5% of the time. The aPTT result fell in a higher category than the anti-Xa result 61.5% of the time, and earlier studies reported discordance rates of 40%–75% (Li 2024).
- Associated findings. High INR, high total bilirubin and low platelet count, hemoglobin, prealbumin and haptoglobin were associated with a high aPTT relative to anti-Xa. A lower antithrombin antigen level was associated with a higher aPTT for any anti-Xa level (Li 2024).
- Acute-phase proteins. Elevated factor VIII and fibrinogen make the aPTT discordant with the anti-Xa result, and UFH is then titrated by anti-Xa (Reardon 2026).
Anti-Xa assay principle and interferences
The chromogenic anti-Xa assay measures residual factor Xa after neutralization by the heparin–antithrombin complex. Chromogen generation is inversely proportional to the heparin concentration. The assay measures only antithrombin-catalyzed inhibition of factor Xa and does not capture the anti-IIa activity of UFH (Reardon 2026).
- Assay configuration. Configurations with exogenous antithrombin, with dextran sulfate or with neither give markedly different results on the same sample (Ozment 2024).
- Factor Xa-inhibiting DOACs. Rivaroxaban, apixaban and edoxaban greatly raise heparin-calibrated anti-Xa results. Drug-specific assays, ex vivo DOAC removal or sampling at trough are required (Reardon 2026).
- ECMO. Bilirubin and free hemoglobin interfere with chromogenic anti-Xa results in patients on extracorporeal membrane oxygenation (ECMO) (Reardon 2026).
| Influence | ACT | Anti-Xa | aPTT (UFH) | Source |
|---|---|---|---|---|
| Heparin contamination | ↑ | ↑ | ↑ | Ozment 2024 |
| Elevated fibrinogen and factor VIII | ↓ | ↔ | ↓ | Ozment 2024 |
| Antithrombin deficiency | ↓ | ↓ (without added antithrombin) | ↓ | Ozment 2024 |
| Thrombocytopenia below about 50 × 10⁹/L | ↑ | ↔ | ↔ | Ozment 2024 |
| Lupus anticoagulant | ↑ | ↔ | ↑ | Ozment 2024 |
| Procoagulant factor deficiency | ↑ | ↔ | ↑ | Ozment 2024 |
| High triglyceride, total bilirubin or free hemoglobin | ↔ | ↓ above an analyzer-specific threshold | ↔ or ↑ | Ozment 2024 |
| Hypothermia | ↑ | ↔ (assay run at 37 °C) | ↔ (assay run at 37 °C) | Ozment 2024 |
- Specimens. Underfilled or overfilled tubes, analysis delayed beyond 2 h and gross hemolysis from sampling require a new sample (Ozment 2024).
- Pediatric ECMO. The Pediatric ECMO Anticoagulation CollaborativE consensus suggests combining a time-to-clot assay (ACT, aPTT, PT/INR or viscoelastic testing) with the anti-Xa assay. Poor correlation between ACT or aPTT and anti-Xa in ECMO reflects ongoing factor and platelet consumption (Ozment 2024).
- Adult ECMO. The ISTH recommends anti-Xa monitoring on ECMO with a target of 0.3–0.5 IU/mL (Reardon 2026).
Low-molecular-weight heparin monitoring
- Indications. Routine anti-Xa monitoring is not recommended in standard patient groups, because therapeutic ranges linked to clinical outcomes are lacking. Monitoring may be considered in pregnancy, renal impairment, ECMO and extremes of body weight (Reardon 2026).
- Timing. Peak levels are drawn about 4 h after a dose at steady state (Reardon 2026). In body weight above 120 kg, a selective peak level is drawn 3–5 h after the third or fourth dose (Reardon 2026).
- Renal impairment. Reported peak targets are about 0.5–1.0 IU/mL for twice-daily regimens, and trough levels detect accumulation (Reardon 2026).
- Pregnancy. Monitoring is reserved for high-risk circumstances such as recurrent VTE, renal impairment or extremes of weight. In those settings, trough levels above 0.1 IU/mL and 4-h peak levels of 0.5–1.0 IU/mL are maintained (Reardon 2026).
Heparin resistance
- Definition. Heparin resistance is usually defined as minimal change in aPTT or ACT, or a subtherapeutic anti-Xa level, despite standard or increased UFH dosing (for example, 35,000 units or more per day). In cardiopulmonary bypass, it is often defined as a requirement for more than 500 U/kg to reach an ACT of 400–480 s (Reardon 2026).
- Frequency. It is reported in 4%–26% of adults undergoing cardiac surgery with cardiopulmonary bypass (Reardon 2026).
| Mechanism | Laboratory clue | Source |
|---|---|---|
| Antithrombin deficiency | Low anti-Xa despite a high heparin dose; low antithrombin activity | Reardon 2026 |
| Acute-phase proteins (factor VIII, fibrinogen, VWF) | aPTT discordant with anti-Xa | Reardon 2026 |
| PF4 neutralization | High platelet count | Reardon 2026 |
| Andexanet alfa exposure | Recent DOAC reversal; non-prolongation of the ACT | Reardon 2026; Andexxa label |
| Pseudo-resistance | Results inconsistent with the clinical picture; sampling from a line | Reardon 2026 |
- Antithrombin after heparin. Antithrombin levels may fall by about 30% after heparin is started and then rise gradually (Reardon 2026). Antithrombin assays are described in Thrombophilia Testing and Antiphospholipid Antibody Testing.
Activated clotting time and protamine
- ACT. The ACT is a point-of-care whole-blood clotting test and the standard of care for monitoring high-dose UFH in cardiac procedures. Hypothermia, hemodilution, platelet count and factor deficiencies affect it (Reardon 2026).
- ACT target in cardiopulmonary bypass. Multidisciplinary guidelines recommend an ACT of at least 480 s, or at least 400 s with maximally activated devices (Reardon 2026). The ACT therapeutic range is validated for cardiopulmonary bypass and varies by analyzer (Ozment 2024).
- Protamine. Protamine binds UFH electrostatically and neutralizes it within minutes. Dosing targets 1 mg protamine per about 100 U of UFH given in the previous 2–3 h (Reardon 2026).
- Excess protamine. Increasing amounts of protamine prolong clotting times in whole blood through effects on platelet function, factor V activation and thrombin generation (Reardon 2026).
- Heparin rebound. Reappearance of heparin activity after protamine reversal is shown by an increased thrombin time, anti-Xa activity and ACT (Reardon 2026).
- LMWH. Protamine neutralizes the anti-IIa activity of LMWH more completely than its anti-Xa activity (Reardon 2026).
Vitamin K antagonist monitoring by the INR
- INR principle. The INR formula and the ISI are described in Coagulation Specimen Collection, Screening Tests and Mixing Studies.
- ISI verification. Local ISI calibration or verification uses at least 20 normal plasmas and 60 stable vitamin K antagonist-treated samples with INR about 1.5–4.5 (Zou 2026).
- Point-of-care INR. Bias against the central laboratory increases at higher INR values, and method comparison uses an acceptable paired difference of about 0.5 INR units (Zou 2026). Point-of-care INR devices are described in Coagulation Specimen Collection, Screening Tests and Mixing Studies.
- Factor VII. Factor VII has a short half-life of about 4–6 h (Bashir 2026). The Fiix-PT measures factors II and X and reduces the effect of fluctuation in factor VII on vitamin K antagonist monitoring (Zou 2026).
- DOACs and the INR. DOAC effects on the PT are drug-specific and reagent-dependent and do not fit the vitamin K antagonist calibration model (Zou 2026).
- Pharmacogenetics. A dosing algorithm with clinical and CYP2C9 and VKORC1 genetic data predicted the stable warfarin dose better than a clinical algorithm in patients needing 21 mg or less, or 49 mg or more, per week (Klein 2009).
Direct thrombin inhibitor monitoring
- Bivalirudin. The aPTT target for bivalirudin is usually 60–90 s, and the aPTT loses linearity at high doses (Ozment 2024).
- Argatroban and the INR. Argatroban raises the INR during transition to warfarin. A chromogenic factor X level of 45% or less predicted an INR of 2 or more after argatroban was stopped, with a sensitivity of 93% and a specificity of 78% (Arpino 2005).
- Labeled transition rule. Argatroban and warfarin produce a combined effect on the INR, but co-therapy exerts no additional effect on vitamin K-dependent factor Xa activity. At argatroban doses up to 2 mcg/kg/min, argatroban can be stopped when the INR exceeds 4 on combined therapy, and the INR is repeated 4–6 h later. If the repeat INR is below the therapeutic range, argatroban is resumed and the procedure repeated daily. At higher doses, the argatroban dose is first reduced to 2 mcg/kg/min (argatroban label).
- Chromogenic factor X in transition. In a retrospective study, a chromogenic factor X level of 45% or less predicted a therapeutic INR with a sensitivity of 63.2% overall and 78.2% after at least 5 days of overlap. The authors recommended at least 5 days of overlap and a level of 45% or less before argatroban is stopped (Austin 2012).
- Dabigatran. The thrombin time, ecarin clotting time and diluted thrombin time (Hemoclot) are sensitive to dabigatran. The PT is less sensitive, is not recommended (van Ryn 2010) and is not suitable for excluding dabigatran (Zou 2026). The aPTT gives a qualitative assessment and is less sensitive at supratherapeutic levels (van Ryn 2010). With direct thrombin inhibitors, the thrombin time is prolonged and the reptilase time is normal (Alotaibi 2026).
Laboratory measurement of DOACs: ICSH 2018 and the 2021 update
- ICSH 2018. The first International Council for Standardization in Haematology (ICSH) DOAC document covered preanalytical variables (sampling time, sample type and stability), analytical methods (reference, screening and quantitative methods) and postanalytical steps (reporting units and quality assurance) for dabigatran, rivaroxaban, apixaban and edoxaban. It also addressed the limits of the PT, aPTT, viscoelastic and point-of-care tests, method validation and external quality assessment (Gosselin 2018).
- ICSH 2021 update. The 2021 document supplements the 2018 recommendations. It adds betrixaban, the reversal agent andexanet alfa, patient-population considerations and updates on point-of-care testing (Douxfils 2021).
- Quantitative methods. Anti-Xa or anti-IIa assays calibrated for the specific drug are preferred when quantitative information is useful. Reagent sensitivity and laboratory calibration affect results, and international calibrators are needed for each drug (Douxfils 2018).
- Reference method and thresholds. Liquid chromatography–tandem mass spectrometry (LC-MS/MS) is the gold standard for DOAC quantification, and drug-specific anti-Xa assays correlate well with it. Drug-specific assays are preferred for quantifying factor Xa inhibitors above 30–50 ng/mL. Heparin-calibrated anti-Xa assays have a lower limit of detection of 20–30 ng/mL for factor Xa inhibitors and may help exclude a relevant concentration in laboratories with validated protocols (Mithoowani 2026).
- Clinical thresholds and sampling. Therapeutic ranges for DOACs are undefined. The ISTH suggests that patients with DOAC levels below 30–50 ng/mL are unlikely to benefit from reversal for major bleeding or before urgent surgery. Levels are drawn at peak (1–4 h after a dose) or at trough (just before the next dose), after at least four to five doses for steady state (Mithoowani 2026).
- Interference in other tests. DOACs cause false-positive or false-negative results in hemostasis tests. Specific assays and sampling at trough concentration reduce these errors (Douxfils 2018). DOAC effects on lupus anticoagulant and thrombophilia assays are covered in Thrombophilia Testing and Antiphospholipid Antibody Testing.
- DOAC-sensitive PT. A dual PT system reports a DOAC normalized ratio from a DOAC-sensitive reagent and an INR from a DOAC-insensitive reagent. It showed 100% sensitivity for edoxaban concentrations above 50 ng/mL (Zou 2026).
| Drug class | Preferred quantitative test | Screening test behavior | Source |
|---|---|---|---|
| Direct factor Xa inhibitors | Drug-calibrated anti-Xa assay | Heparin-calibrated anti-Xa greatly raised | Douxfils 2018; Reardon 2026 |
| Dabigatran | Diluted thrombin time or ecarin assay | Thrombin time very sensitive; PT insensitive; aPTT qualitative | van Ryn 2010; Zou 2026 |
Laboratory effects of reversal agents
- Idarucizumab. In 503 patients, 5 g of idarucizumab produced a median maximum reversal of 100% by diluted thrombin time or ecarin clotting time within 4 h (Pollack 2017). Elevated coagulation parameters (aPTT or ecarin clotting time) reappeared 12–24 h after the 5-g dose in a limited number of patients, and an additional 5-g dose may be considered for recurrent bleeding with elevated parameters (Praxbind label).
- Andexanet alfa. In healthy older volunteers, an andexanet bolus reduced anti-Xa activity by 94% with apixaban and 92% with rivaroxaban (Siegal 2015).
- Anti-Xa interference after andexanet. Commercial anti-Xa assays are unsuitable after andexanet. The high sample dilution promotes dissociation of the inhibitor from andexanet and gives falsely elevated anti-Xa results (Andexxa label).
- Re-elevation. Anti-Xa activity returns to placebo levels about 2 h after completion of the andexanet bolus or infusion (Andexxa label).
- Heparin unresponsiveness. Unresponsiveness to UFH, with non-prolongation of the ACT, has occurred after andexanet (Andexxa label).
Pretest probability of HIT: the ASH 2018 guideline and the 4Ts score
The ASH 2018 HIT guideline contains 33 recommendations. Strong recommendations include use of the 4Ts score over a gestalt estimate of pretest probability and no HIT laboratory testing or empiric treatment in patients with a low-probability score (Cuker 2018). The ASH guideline recommends an anti-PF4/heparin immunoassay, such as an ELISA, as the first-line laboratory test (Marchetti 2021).
| 4Ts component | 2 points | 1 point | 0 points | Source |
|---|---|---|---|---|
| Thrombocytopenia | Fall >50% and nadir ≥20 × 10⁹/L | Fall 30%–50% or nadir 10–19 × 10⁹/L | Fall <30% or nadir <10 × 10⁹/L | Ampatzidou 2025 |
| Timing of the fall | Clear onset on days 5–10, or ≤1 day with heparin exposure in the previous 30 days | Consistent with days 5–10 but unclear, onset after day 10, or ≤1 day with exposure 30–100 days earlier | Fall within 4 days without recent exposure | Ampatzidou 2025 |
| Thrombosis or other sequelae | New thrombosis, skin necrosis or acute systemic reaction after a heparin bolus | Suspected thrombosis, progressive or recurrent thrombosis, or erythematous skin lesions | None | Ampatzidou 2025 |
| Other causes of thrombocytopenia | None evident | Possible | Definite | Ampatzidou 2025 |
A total of 6–8 indicates high, 4–5 intermediate and 0–3 low pretest probability (Ampatzidou 2025).
- Low score. In the original two-center study, 1 of 64 and 0 of 55 patients with low scores tested positive for HIT antibodies (Lo 2006).
- Meta-analysis. In 3068 patients, the negative predictive value of a low-probability score was 0.998. The positive predictive values of intermediate and high scores were 0.14 and 0.64 (Cuker 2012).
- Cardiac surgery. The 4Ts score reliably excludes HIT but lacks specificity after cardiopulmonary bypass (Ampatzidou 2025).
- Testing sequence. Diagnosis of HIT requires immunological detection of anti-PF4/heparin antibodies and confirmation of their platelet-activating potential (Althaus 2026). The usual work-up is a PF4-dependent screening immunoassay, such as an ELISA or a rapid latex immunoturbidimetric assay, followed by a heparin-dependent platelet activation assay (Yates 2026).
- Rapid algorithms. A Bayesian algorithm combining the 4Ts score with an IgG-specific chemiluminescent immunoassay and a particle gel immunoassay correctly classified more than 95% of patients within 60 min of laboratory work (Marchetti 2021).
Immunoassays for anti-PF4/heparin antibodies
- ELISA performance. Polyspecific (IgG, IgA and IgM) and IgG-specific ELISAs have a sensitivity of 97% and a negative predictive value of 99%. Their specificity is 82% and 87%, and the test takes about 4 h (Yates 2026).
- Meta-analysis. Among 128 test evaluations in 15,199 patients, sensitivity above 95% with specificity above 90% was found only for a polyspecific ELISA at an intermediate threshold, the particle gel immunoassay, the lateral flow immunoassay, a polyspecific chemiluminescent immunoassay at a high threshold and an IgG-specific chemiluminescent immunoassay at a low threshold (Nagler 2016).
- Optical density. A weak-positive result of 0.40 to <1.00 OD units indicated a probability of 5% or less of a strong-positive serotonin release assay (SRA). The probability was about 90% at 2.00 OD units or more, and it reached 50% only at 1.40 OD units or more (Warkentin 2008).
- Rapid immunoassays. Rapid immunoassays have analytical turnaround times of 20–30 min. A latex immunoturbidimetric assay had a reported sensitivity of 97.4% and specificity of 94% (Yates 2026).
- Reflex testing. In one laboratory, the latex assay alone had a specificity of 14.9%. Reflex IgG-specific ELISA confirmation of latex-positive samples raised the positive predictive value from 25.3% to 61.2% and reduced SRA send-outs by 61.4% (Yates 2026).
Functional assays for HIT
- Serotonin release assay. The SRA measures platelet release at two heparin concentrations. HIT sera cause release at therapeutic heparin concentrations and not at high concentrations. Specificity in the original study was 99% (1 of 573 controls) (Sheridan 1986).
- Assay types. Platelet activation assays include the SRA, heparin-induced platelet activation (HIPA), platelet aggregation tests, flow cytometry-based assays and heparin-induced multielectrode aggregometry (Althaus 2026).
- Standardization. The 2026 ISTH SSC communication addresses sample collection, donor selection, platelet preparation, heparin concentrations, controls and indeterminate results. Immunoassays cannot separate pathogenic from nonpathogenic antibodies, and platelet activation assays remain poorly standardized and not widely available (Althaus 2026).
- Cardiac surgery. For patients with HIT who need cardiopulmonary bypass, limited intraoperative UFH re-exposure carries a low risk of recurrence when functional assays are negative (Pishko 2026).
Vaccine-induced immune thrombotic thrombocytopenia
- Presentation. In 11 patients after ChAdOx1 nCov-19 vaccination, thrombosis began 5–16 days after vaccination, most often cerebral venous thrombosis. All had thrombocytopenia, and none had received heparin before symptom onset (Greinacher 2021).
- Serology. PF4–heparin ELISA optical densities were high, and a PF4-enhanced platelet activation test detected platelet-activating antibodies (Greinacher 2021).
- Pattern of immunoassays. In vaccine-induced immune thrombotic thrombocytopenia (VITT), PF4 antibodies are detected by ELISA-based assays and are usually missed by other immunoassays that are positive in HIT. Standard heparin concentrations inhibit activation by VITT antibodies in some functional assays (Favaloro 2021).
- Sample dilution. Higher EIA ODs predicted positive PF4-induced platelet activation testing. Of 61 EIA-positive sera with OD >1.0 that were negative in the activation assay, 44.3% became positive at 1:4 to 1:10 dilution (Schönborn 2022).
DIC, Thrombotic Microangiopathy and Viscoelastic Testing
Definition. Disseminated intravascular coagulation (DIC) is defined by the ISTH (2025) as an acquired, life-threatening intravascular disorder characterized by systemic coagulation activation, dysregulated fibrinolysis and endothelial injury, resulting in microthrombosis. It arises from various underlying etiologies and progresses from a potentially asymptomatic early phase to an advanced phase with hemorrhage, organ dysfunction or both (Iba 2025). Thrombotic microangiopathies (TMAs), including thrombotic thrombocytopenic purpura (TTP) and complement-mediated hemolytic uremic syndrome (HUS), are defined by thrombocytopenia, microangiopathic hemolytic anemia (MAHA) and small vessel thrombosis (Scully 2023). Viscoelastic tests measure clot initiation, clot strength and fibrinolysis in whole blood (Bashir 2026).
Related page: Coagulation Specimen Collection, Screening Tests and Mixing Studies (PT, aPTT, fibrinogen and D-dimer methods) Related page: Clotting Factor Assays, Factor Inhibitors and Interference by Hemophilia Therapies (factor patterns in liver disease and vitamin K deficiency) Related page: Anticoagulant Monitoring, DOAC Measurement and Heparin-Induced Thrombocytopenia Testing (ACT and heparin monitoring in cardiac surgery) Related page: Therapeutic Apheresis, ASFA Indications and Hematopoietic Progenitor Cell Products (therapeutic plasma exchange and caplacizumab in TTP) Related page: Transfusion Indications, Massive Transfusion, Platelet Refractoriness and Patient Blood Management (massive transfusion and viscoelastic-guided transfusion)
Definition of DIC in the ISTH 2025 update
- Previous definition. The ISTH definition of 2001 described DIC as an acquired syndrome characterized by intravascular activation of coagulation with loss of localization, arising from different causes, which can originate from and damage the microvasculature and cause organ dysfunction (Iba 2019).
- 2025 definition. The 2025 definition adds dysregulated fibrinolysis, endothelial injury and the progression from an early phase to an advanced phase (Iba 2025).
- Phases. The 2025 framework classifies DIC as pre-DIC, early-phase DIC and overt DIC. Early-phase DIC, also called subclinical or compensated DIC, has laboratory abnormalities before clinical signs (Iba 2026a).
- Phenotypes. Thrombotic DIC shows microvascular thrombosis and organ dysfunction. Hemorrhagic DIC shows bleeding from consumption of coagulation factors (Iba 2026a).
- Disease-tailored criteria. The 2025 update proposes criteria for early-phase DIC tailored to the underlying disease, such as sepsis, trauma or malignancy (Iba 2025; Iba 2026a).
- Underlying disease. Sepsis-associated DIC is often complicated by organ dysfunction. DIC associated with hematologic malignancy is complicated predominantly by bleeding (Iba 2019).
Overt DIC score: the ISTH 2001 score and the 2025 modification
The ISTH 2001 overt DIC score uses four routine tests. A total of 5 or more is compatible with overt DIC (Taylor 2001; Matsuoka 2024).
| Test | Points | Source |
|---|---|---|
| Platelet count (× 10⁹/L) | ≥100: 0; 50 to <100: 1; <50: 2 | Iba 2019; Matsuoka 2024 |
| Fibrin-related marker (D-dimer, FDP or soluble fibrin) | No increase: 0; moderate increase: 2; strong increase: 3 | Iba 2019; Matsuoka 2024 |
| Prolongation of PT (s) | <3: 0; ≥3 to <6: 1; ≥6: 2 | Iba 2019; Matsuoka 2024 |
| Fibrinogen (g/L) | ≥1.0: 0; <1.0: 1 | Iba 2019; Matsuoka 2024 |
The 2025 overt DIC score for late-phase DIC is shown below as reported in an open case report that applied it (Song 2026).
| Test (2025 overt DIC score) | Points | Source |
|---|---|---|
| Platelet count (× 10⁹/L) | >100: 0; 50–100: 1; <50: 2 | Song 2026 |
| D-dimer | ≤3 × upper limit of normal: 0; >3 × upper limit of normal: 2; >7 × upper limit of normal: 3 | Song 2026; Iba 2026a |
| Prolongation of PT (s) | <3: 0; ≥3 to <6: 1; ≥6: 2 | Song 2026 |
| Fibrinogen (g/L) | >1.0: 0; <1.0: 1 | Song 2026 |
| Total | ≥5 compatible with overt DIC | Song 2026 |
The Iba 2026 summary expresses the PT item as PT-INR.
- 2025 modification. The 2025 update modifies the overt DIC criteria and score for late-phase DIC (Iba 2025). It replaces the moderate and strong increase of a fibrin-related marker with D-dimer cut-offs. D-dimer above 3 times the upper limit of normal scores 2 points, and D-dimer above 7 times the upper limit scores 3 points. Platelet count, PT and fibrinogen remain in the score (Iba 2026a; Song 2026).
- Fibrin-related marker in 2001. The 2001 score grades the fibrin-related marker as a moderate or strong increase (Matsuoka 2024). The cut-off values for these markers were not clearly defined, and the ISTH score diagnosed infection-related DIC later than the Japanese criteria (Iba 2019).
- Score below threshold. In a 2026 cohort of 1027 infected adults with complete score components, 94.8% were below the ISTH 2001 overt DIC threshold, including 44 of 60 patients with septic shock (Zhou 2026).
Sepsis-induced coagulopathy and other DIC criteria
- SIC in the 2025 framework. The sepsis-induced coagulopathy (SIC) score is acknowledged as a tool for detecting early-phase DIC in sepsis (Iba 2026a).
| SIC item | 0 points | 1 point | 2 points | Source |
|---|---|---|---|---|
| PT-INR | ≤1.2 | >1.2 | >1.4 | Iba 2017 |
| Platelet count (× 10⁹/L) | ≥150 | <150 | <100 | Iba 2017 |
| Total SOFA (respiratory, cardiovascular, hepatic, renal) | 0 | 1 | ≥2 | Iba 2017 |
- SIC threshold. SIC is diagnosed with a total of 4 or more, with the PT and platelet items together exceeding 2 (Iba 2017).
- SIC and overt DIC. In an ISTH SSC analysis, almost all patients with overt DIC had SIC, and SIC preceded overt DIC in every case. Mortality was 32.5% with overt DIC and 23.1% with SIC (Iba 2019).
- Proposed SIC-2. Removal of the SOFA component preserved prediction of overt DIC in 18,086 patients with sepsis, with AUC values of 0.850 and 0.854 for the two scores (Iba 2026b).
- JAAM criteria. The Japanese Association for Acute Medicine (JAAM) criteria detected DIC earlier than the ISTH and Japanese Ministry of Health and Welfare criteria. The revised JAAM criteria exclude fibrinogen (Gando 2006).
- Antithrombin. The Japanese Society on Thrombosis and Hemostasis criteria include antithrombin of 70% or less as a scoring item (Iba 2019). Antithrombin assays are covered in Thrombophilia Testing and Antiphospholipid Antibody Testing.
DIC and the coagulopathy of liver disease
- Conventional tests in cirrhosis. The PT and aPTT do not fully activate protein C and do not reflect the balance of procoagulant and anticoagulant factors in cirrhosis (Tripodi 2005).
- Thrombin generation. Thrombin generation without thrombomodulin is impaired in cirrhosis. With added thrombomodulin, patients generate as much thrombin as controls (Tripodi 2005).
- Rebalanced hemostasis. End-stage liver disease reduces protein C, protein S and antithrombin (Bashir 2026). Factor VIII and von Willebrand factor (VWF) in liver disease are described in Clotting Factor Assays, Factor Inhibitors and Interference by Hemophilia Therapies.
- INR in liver disease. Disproportionate factor reduction makes the INR reagent-dependent in advanced liver disease. A cirrhosis-specific INR (INR liver) uses an ISI derived from patients with chronic liver disease (Zou 2026).
- Liver failure in DIC criteria. The Japanese criteria define liver failure by a PT activity of 40% or less or an INR of 1.5 or more, or cirrhosis of Child–Pugh class B or C, as a modifier of DIC scoring (Iba 2019).
Hyperfibrinolysis and fibrinolytic phenotypes
- Acute promyelocytic leukemia (APL). Severe bleeding, particularly intracranial, is the major cause of early death in APL. APL is associated with coagulation activation, hyperfibrinolysis and thrombocytopenia (Hisada 2024).
- APL mechanisms. Proposed pathways include tissue factor, urokinase plasminogen activator and its receptor, annexin A2 with S100A10 and tissue plasminogen activator (t-PA), and podoplanin with C-type lectin-like receptor 2 (Hisada 2024).
- Liver transplantation. Unregulated t-PA release in the anhepatic phase causes hyperfibrinolysis that peaks just before reperfusion (Bashir 2026).
- Fibrinolysis in sepsis. Sepsis-associated DIC is characterized by coagulation activation with suppression of fibrinolysis (Iba 2017).
- Viscoelastic detection. Elevated LY30 or LY60 on TEG indicates hyperfibrinolysis. On ROTEM, comparison of EXTEM with APTEM or change in lysis parameters identifies hyperfibrinolysis (Bashir 2026).
Trauma-induced coagulopathy
- Acute traumatic coagulopathy. In 1088 trauma patients, 24.4% had coagulopathy on arrival. Mortality was 46.0% with coagulopathy and 10.9% without. Coagulopathy increased with injury severity and was unrelated to the volume of intravenous fluid (Brohi 2003).
- Fibrinolytic phenotypes. Rapid TEG LY30 thresholds define fibrinolysis shutdown (<0.9%), physiologic fibrinolysis (0.9%–2.9%) and hyperfibrinolysis (>2.9%). Mortality was 20% with shutdown, 16% with hyperfibrinolysis and 9% with physiologic fibrinolysis (Moore 2017).
- Shutdown mechanism. Shutdown is associated with plasminogen activator inhibitor-1 (PAI-1) activity. A subgroup shows inadequate t-PA release (Moore 2017).
- Resuscitation. Massive transfusion and viscoelastic-guided transfusion are covered in Transfusion Indications, Massive Transfusion, Platelet Refractoriness and Patient Blood Management.
Hemostatic changes in pregnancy and obstetric hemorrhage
| Parameter | Change in normal pregnancy | Source |
|---|---|---|
| Fibrinogen, VWF and factor VIII | Rise to at least 2–3 times normal | Cox 2026 |
| Factor XIII | Decreases gradually, usually within the reference range | Cox 2026 |
| Fibrinolysis | Reduced, with increased PAI-1 and placental PAI-2 | Cox 2026 |
| D-dimer | Increases gradually | Cox 2026 |
| Platelet count | Mild reduction; 5%–10% of women at term have a count below the nonpregnant reference range; usually >100 × 10⁹/L at delivery | Cox 2026 |
Free protein S antigen in pregnancy is described in Thrombophilia Testing and Antiphospholipid Antibody Testing.
- Fibrinogen in postpartum hemorrhage. Fibrinogen as a predictor of severe postpartum hemorrhage (Charbit 2007) is described in Transfusion Indications, Massive Transfusion, Platelet Refractoriness and Patient Blood Management.
- Acute obstetric coagulopathy. In the OBS+ study, a small group had acute obstetric coagulopathy with low Clauss fibrinogen (median 2.1 g/L). Fibrinogen antigen fell less than Clauss fibrinogen, which indicates acquired fibrinogen dysfunction from excessive plasmin generation (Cox 2026).
- Obstetric causes. Placental abruption, amniotic fluid embolism, preeclampsia and HELLP syndrome (hemolysis, elevated liver enzymes and low platelets) cause peripartum coagulopathy (Cox 2026).
- Liver dysfunction in pregnancy. In a prospective study of 4377 deliveries, abnormal liver tests occurred in 3%. HELLP syndrome contributed in 30 patients and acute fatty liver of pregnancy in 5 (Ch'ng 2002).
- HELLP criteria. The Tennessee criteria for HELLP syndrome require hemolysis (schistocytes, low haptoglobin or bilirubin >1.2 mg/dL), LDH >600 IU/L, AST or ALT >70 IU/L and platelets ≤100 × 10⁹/L. Class 1 by platelet nadir is <50 × 10⁹/L (Trivedi 2025).
- AFLP criteria. The Swansea criteria for acute fatty liver of pregnancy require six or more features without another explanation. Laboratory features include bilirubin >14 µmol/L, glucose <4 mmol/L, urate >340 µmol/L, white cell count >11 × 10⁹/L, AST or ALT >42 IU/L, ammonia >47 µmol/L, creatinine >150 µmol/L and PT >14 s or aPTT >34 s. Compared with HELLP, AFLP is more often associated with hypoglycemia and a prolonged PT (Trivedi 2025).
- TTP in pregnancy. A postpartum LDH-to-AST ratio above 70 helps separate TTP from HELLP, and ADAMTS13 activity <10% is the most sensitive and specific test for TTP (Trivedi 2025).
- Fibrinogen replacement. Cryoprecipitate and fibrinogen replacement are covered in Transfusion Indications, Massive Transfusion, Platelet Refractoriness and Patient Blood Management.
Thrombotic thrombocytopenic purpura: ISTH 2020 diagnosis and the 2025 focused update
- Forms. About 95% of TTP is immune TTP (iTTP) from autoantibodies against ADAMTS13. Fewer than 5% is congenital TTP (cTTP) from ADAMTS13 mutations (Meng 2026). The incidence is 2–6 per million (Zheng 2020).
- Population. The ISTH guideline addresses patients with platelets <100 × 10⁹/L, MAHA and relatively preserved renal function (Zheng 2020).
- Sample timing. The timing of the ADAMTS13 sample in relation to TPE is described in Therapeutic Apheresis, ASFA Indications and Hematopoietic Progenitor Cell Products.
- Turnaround. ADAMTS13 activity results within 72 h are ideal, and results within 72 h to 7 days are acceptable (Zheng 2020).
- Pretest probability. A probability above 90% is high. Clinical assessment or a risk score such as the PLASMIC or French score estimates it, and the panel recommends no specific score (Zheng 2020).
| ADAMTS13 activity | ISTH 2020 interpretation | Source |
|---|---|---|
| <10 IU/dL (<10% of normal) | Positive result | Zheng 2020 |
| 10–20 IU/dL | Equivocal result; clinical judgment required | Zheng 2020 |
| >20 IU/dL (>20% of normal) | Negative result; other diagnoses considered | Zheng 2020 |
- Treatment pathway. TPE, corticosteroids and caplacizumab for TTP are covered in Therapeutic Apheresis, ASFA Indications and Hematopoietic Progenitor Cell Products.
- 2025 focused update. The 2025 update made no change to the recommendations for iTTP. For cTTP in remission, it issued a new strong recommendation for recombinant ADAMTS13 over plasma infusion and revised a previous recommendation to suggest plasma over a watch-and-wait approach (Zheng 2025).
- Remission monitoring. In remission, ADAMTS13 activity is usually measured monthly for 3 months, every 3 months for the first year and every 6–12 months when stable (Zheng 2025).
- Pregnancy after TTP. Relapse risk is high when pregnancy begins with ADAMTS13 activity below the normal range. A fall below about 30 IU/dL prompts closer management (Zheng 2025).
- BSH guidance. The BSH 2023 guideline covers TTP and related TMAs, including complement-mediated HUS (Scully 2023). The BSH 2026 laboratory guidance addresses methods for testing ADAMTS13 deficiency (MacDonald 2026).
ADAMTS13 activity, inhibitor and antibody assays
- FRETS-VWF73. A synthetic 73-amino-acid VWF peptide carries a fluorophore and a quencher. Cleavage by ADAMTS13 relieves quenching, and quantitative results are available within about 1 h in a 96-well format (Kokame 2005).
- Sensitivity of FRETS-VWF73. The lower limit of detection is <3–5%, sufficient for severe deficiency. Hyperbilirubinemia, hemoglobin and neutrophil peptides influence results (Meng 2026).
- Other activity methods. A chromogenic ELISA uses a tagged VWF73 substrate and an antibody to the cleaved end (Meng 2026). In the ISTH review, pooled sensitivity and specificity at <10% were 94% and 99% for fluorescence energy transfer assays, 93% and 100% for collagen-binding assays and 69% and 97% for immunoassays (Zheng 2020).
- Turnaround. In-house FRETS assays need skilled technicians, and results usually take more than 1 day. Commercial rapid assays (a chromogenic ELISA and an automated chemiluminescent immunoassay) return results in less than 1 h (Meng 2026).
| Rapid ADAMTS13 activity assay | Sensitivity (95% CI) | Specificity (95% CI) | Source |
|---|---|---|---|
| Automated chemiluminescent immunoassay (3533 samples) | 0.98 (0.94–1.00) | 0.99 (0.97–1.00) | Deshpande 2025 |
| Rapid FRET assay (331 samples) | 0.93 (0.86–0.96) | 0.98 (0.95–0.99) | Deshpande 2025 |
| Semiquantitative color-chart screen (343 samples) | 0.98 (0.42–1.00) | 0.87 (0.78–0.92) | Deshpande 2025 |
- Discrepant rapid results. Discrepancies between rapid and reference assays occur with low clinical suspicion, iTTP in remission, sepsis, DIC, malignancy, pregnancy and icteric samples (Deshpande 2025).
- Inhibitor (Bethesda-type) assay. Patient plasma is serially diluted with pooled normal plasma, and ADAMTS13 activity is measured by FRETS-VWF73. The titer is calculated from the dilutions needed to normalize activity. An inhibitor of 2 or more Bethesda units/mL with activity <10% was associated with lower survival (Meng 2026). The Bethesda calculation is described in Clotting Factor Assays, Factor Inhibitors and Interference by Hemophilia Therapies.
- Limits of the inhibitor assay. It detects only inhibitory antibodies. Non-inhibitory IgG autoantibodies were found in 29% of idiopathic TTP, so a negative inhibitor assay does not exclude iTTP (Meng 2026).
- Anti-ADAMTS13 IgG ELISA. It detects neutralizing and non-neutralizing IgG and separates iTTP from cTTP (Meng 2026).
- ADAMTS13 antigen. Antigen testing is not routinely used for diagnosis or management (Meng 2026).
Congenital TTP and ADAMTS13 genetics
- Variants. More than 200 pathogenic ADAMTS13 variants are known. Congenital TTP is also called Upshaw–Schulman syndrome (Meng 2026).
- Presentation. cTTP is usually diagnosed in children or teenagers, and in adults often during pregnancy. It may account for 25%–50% of TTP in children and pregnant women, and for 27% of pregnancy-onset TTP in the French registry (Meng 2026).
- Diagnostic clue. Severe ADAMTS13 deficiency that persists in clinical remission, without MAHA or thrombocytopenia, suggests cTTP (Meng 2026).
PLASMIC and French scores for severe ADAMTS13 deficiency
| Item | French score | PLASMIC score | Source |
|---|---|---|---|
| Platelet count <30 × 10⁹/L | +1 | +1 | Zheng 2020 |
| Creatinine | <2.26 mg/dL (+1) | <2.0 mg/dL (+1) | Zheng 2020 |
| Hemolysis (indirect bilirubin >2 mg/dL, reticulocytes >2.5% or undetectable haptoglobin) | Not scored; part of the TMA definition | +1 | Zheng 2020 |
| No active cancer in the previous year | Not scored; assumed in the score definition | +1 | Zheng 2020 |
| No solid-organ or stem cell transplant | Not scored; assumed in the score definition | +1 | Zheng 2020 |
| INR <1.5 | Not scored; DIC assumed absent in the score definition | +1 | Zheng 2020 |
| MCV <90 fL | Not included | +1 | Zheng 2020 |
| Probability of activity <10% | 0: 2%; 1: 70%; 2: 94% | 0–4: 0–4%; 5: 5–24%; 6–7: 62–82% | Zheng 2020 |
- PLASMIC derivation. The seven-component PLASMIC score was derived in 214 patients with TMA. The C statistic was 0.96 in derivation, 0.95 in internal validation and 0.91 in external validation (Bendapudi 2017).
- French score derivation. Creatinine ≤200 µmol/L (2.26 mg/dL), platelet count <30 × 10⁹/L and antinuclear antibody positivity predicted severe acquired ADAMTS13 deficiency. The AUROC fell from 0.951 to 0.930 when continuous variables were dichotomized (Coppo 2010).
Hemolytic uremic syndrome and complement-mediated TMA
- Shiga toxin-producing Escherichia coli (STEC). All stools submitted for routine testing from patients with acute community-acquired diarrhea are cultured for E. coli O157:H7 and tested at the same time with an assay that detects Shiga toxins, which identifies non-O157 STEC (Gould 2009).
- Atypical HUS. Complement plays a primary role in atypical HUS. The KDIGO Controversies Conference addressed genetic and acquired drivers of disease (Goodship 2017).
- Terminology. The BSH 2023 guideline uses the term complement-mediated HUS (Scully 2023).
- Laboratory work-up of complement-mediated HUS. ADAMTS13 activity is measured first to separate atypical HUS from TTP (Jesiołowski 2026), and stool testing for STEC excludes STEC-associated HUS (Gould 2009). Variants in complement regulators or alternative-pathway genes (CFH, CFI, CD46/MCP, C3, CFB) are present in most patients, CFH most often. Low C3 with normal C4, reduced CH50 and other evidence of alternative-pathway activation support complement dysregulation but occur in other diseases. Anti-factor H autoantibodies indicate an acquired driver (Jesiołowski 2026).
Schistocyte identification and counting: ICSH 2012 and the 2021 update
- Identification (2012). Schistocytes are identified by positive criteria: helmet cells, small irregular triangular or crescent-shaped cells, pointed projections and lack of central pallor (Zini 2012).
- Threshold (2012). A schistocyte count above 1% supports TMA in the absence of other severe red cell shape abnormalities (Zini 2012).
- Reference ranges (2021). The 2021 update proposed reference values of 1% or less for healthy adults and full-term neonates, and 5% or less for preterm infants. More than 1% is suspicious for TMA (Zini 2021).
- Automated fragment counts. The fragmented red cell count of automated analyzers is a screening tool, and its absence excludes schistocytes on the blood film (Zini 2021).
Viscoelastic testing: TEG and ROTEM principles
- Activators. TEG uses kaolin to initiate clotting. ROTEM uses ellagic acid for INTEM and tissue factor for EXTEM (Brito 2026).
- Devices. TEG 6s (FDA approved 2019) and ROTEM sigma (FDA approved 2022) are the second-generation devices that followed TEG 5000 and ROTEM delta (Brito 2026). TEG 6s is a cartridge-based device with resonance-based detection (Bashir 2026).
- Acoustic resonance. The Quantra system measures clot properties by ultrasound-based sonic estimation of elasticity via resonance (SEER) (Bashir 2026).
| Phase | TEG parameter | ROTEM parameter | Definition | Source |
|---|---|---|---|---|
| Clot initiation | R (reaction time) | CT (clotting time) | Time to an amplitude of 2 mm | Brito 2026 |
| Clot kinetics | K and α angle | CFT (clot formation time) and α angle | Time from 2 mm to 20 mm amplitude; slope of the curve | Brito 2026 |
| Clot strength | MA (maximum amplitude) | MCF (maximum clot firmness) | Maximum amplitude of the tracing | Brito 2026 |
| Lysis | LY30, LY60 | CL, LI30, LI60, ML | Percentage lysis at 30 and 60 min after MA (TEG); lysis at specified times or maximum (ROTEM) | Brito 2026; Bashir 2026 |
ROTEM also reports the amplitude at 5, 10 and 15 min (A5, A10 and A15) (Bashir 2026).
| ROTEM assay or TEG cartridge assay | Reagent | Use | Source |
|---|---|---|---|
| EXTEM | Tissue factor | Initiation phase | Bashir 2026 |
| INTEM | Ellagic acid | Amplification phase | Bashir 2026; Brito 2026 |
| FIBTEM | Cytochalasin D | Fibrin-based clot firmness with platelets inhibited | Bashir 2026 |
| HEPTEM | Heparinase | Heparin effect by comparison with INTEM | Bashir 2026 |
| APTEM | Recombinant tissue factor with aprotinin or tranexamic acid | Fibrinolysis by comparison with EXTEM | Volod 2022; Bashir 2026 |
| HEPTEM-equivalent TEG (HTEG) | Kaolin with heparinase | Heparin effect by comparison with kaolin TEG | Volod 2022 |
| NATEM | Recalcification only | Impractical clinically because of the long CT | Volod 2022 |
| TEG citrated functional fibrinogen (CFF) | Kaolin and tissue factor with abciximab, a GPIIb/IIIa inhibitor | Fibrin contribution to clot strength (CFF-MA) | Volod 2022; Bashir 2026 |
Interpretation of viscoelastic patterns
| Pattern | Interpretation | Source |
|---|---|---|
| Prolonged R or CT | Coagulation enzyme deficiency or anticoagulant, such as heparin | Bashir 2026 |
| Prolonged K or CFT, low α angle | Impaired clot propagation, with fibrinogen contributing | Bashir 2026 |
| Low MA or MCF | Reduced clot strength from thrombocytopenia or platelet dysfunction | Bashir 2026 |
| Low FIBTEM MCF | Impaired fibrinogen contribution | Bashir 2026 |
| Elevated LY30 or LY60 | Hyperfibrinolysis | Bashir 2026 |
| Low CLI30 or high ML (ROTEM) | Hyperfibrinolysis | Volod 2022 |
| INTEM prolonged and HEPTEM normal | Heparin effect | Bashir 2026 |
- Limitations. The Quantra cartridge runs at 37 °C, so it does not reflect patient hypothermia, and it is insensitive to hypocalcemia (Bashir 2026). Viscoelastic tests have limited sensitivity for residual UFH after protamine (Reardon 2026).
- Lysis definitions. TEG LY30 is the percentage fall in amplitude 30 min after MA. The ROTEM clot lysis index (CLI30) is the residual percentage of MCF 30 min after CT, and maximum lysis (ML) is the percentage of MCF lost during the run (Volod 2022).
- Representative ranges. Reported normal ranges include kaolin TEG MA 50–70 mm, CFF MA 15–32 mm, EXTEM MCF 49–71 mm, FIBTEM MCF 9–25 mm, kaolin LY30 0–7.5%, CLI30 94–100% and ML <15%. Ranges are device-specific (Volod 2022).
- Thresholds. TEG and ROTEM thresholds differ and are not directly interchangeable (Brito 2026).
- Liver transplantation. TEG-guided and ROTEM-guided strategies were associated with less intraoperative transfusion than conventional testing (Bashir 2026). Transfusion algorithms are covered in Transfusion Indications, Massive Transfusion, Platelet Refractoriness and Patient Blood Management.
Thrombin generation assays
- Principle. Thrombin generation is a global assay of hemostatic function that may help diagnose hypercoagulability and hypocoagulability (Ninivaggi 2021).
- Standardization. Lack of standardization causes poor correlation between assays and laboratories. The 2021 ISTH SSC recommendations cover blood drawing, processing and storage, reagent concentration and source, sample dilution and temperature, calibration and replicates, calculation and interpretation and reference values (Ninivaggi 2021).
References
- Adcock DM, Kressin DC, Marlar RA. Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol. 1997;107(1):105–110. doi:10.1093/ajcp/107.1.105. PMID 8980376
- Adcock DM, Kressin DC, Marlar RA. Minimum specimen volume requirements for routine coagulation testing: dependence on citrate concentration. Am J Clin Pathol. 1998;109(5):595–599. doi:10.1093/ajcp/109.5.595. PMID 9576579
- Adcock DM, Moore GW, Kershaw GW, Montalvão SAL, Gosselin RC. International Council for Standardization in Haematology (ICSH) recommendations for the performance and interpretation of activated partial thromboplastin time and prothrombin time mixing tests. Int J Lab Hematol. 2024;46(5):777–788. doi:10.1111/ijlh.14344. PMID 39009028
- Adcock DM, Moore GW, Montalvão SL, Kershaw G, Gosselin RC. Activated partial thromboplastin time and prothrombin time mixing studies: current state of the art. Semin Thromb Hemost. 2023;49(6):571–579. doi:10.1055/s-0042-1756196. PMID 36055261
- Agouba SM, Bradacova P, Mikler J, et al. Beyond rebalanced haemostasis: haemostatic phenotypes, thrombin generation, and clinical risk in chronic liver disease. TH Open. 2026;10:a29279053. doi:10.1055/a-2927-9053. PMID 42713243
- Al Sharif MA, Mathews N, Tasneem S, et al. Measurement of factor XIII for the diagnosis and management of deficiencies: insights from a retrospective review of 10 years of data on consecutive samples and patients. Res Pract Thromb Haemost. 2025;9(1):102689. doi:10.1016/j.rpth.2025.102689. PMID 40027442
- Albers CA, Cvejic A, Favier R, et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet. 2011;43(8):735–737. doi:10.1038/ng.885. PMID 21765411
- Alijotas-Reig J, Miro-Mur F, Hoxha A, et al. 2023 ACR/EULAR classification criteria for antiphospholipid syndrome: more lights rise but shade remains. RMD Open. 2025;11(3):e006014. doi:10.1136/rmdopen-2025-006014. PMID 40854811
- Alotaibi S, Meunier S, Dargaud Y. Congenital afibrinogenemia and hypofibrinogenemia: genetic basis, pathophysiology, laboratory diagnosis, and management. Hematol Rep. 2026;18(5):72. doi:10.3390/hematolrep18050072. PMID 42931036
- Altahan RM. Acquired platelet disorders. Front Med (Lausanne). 2025;12:1638994. doi:10.3389/fmed.2025.1638994. PMID 41306494
- Althaus K, Bakchoul T, Gruel Y, et al. Standardization of platelet activation tests for the diagnosis of heparin-induced thrombocytopenia: communication from the ISTH-SSC Subcommittee on Immune-Mediated Platelet Disorders. J Thromb Haemost. 2026;24(9):3333–3342. doi:10.1016/j.jtha.2026.05.019. PMID 42208940
- Ampatzidou F, Argyriadou E, Amaniti C, et al. Postoperative thrombocytopenia in cardiac surgery: patterns, differential diagnosis and management of heparin-induced thrombocytopenia (HIT). J Clin Med. 2025;14(24):8765. doi:10.3390/jcm14248765. PMID 41464670
- Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood. 1987;70(1):165–172. PMID 3593964
- Androulakis N, Nioti E, Dilintas A, et al. How I investigate borderline prolonged aPTT: an integrated laboratory approach to mixing studies and factor analysis. Int J Lab Hematol. 2026;48(5):951–960. doi:10.1111/ijlh.70156. PMID 42159456
- Arachchillage DJ, Mackillop L, Chandratheva A, et al. Thrombophilia testing: a British Society for Haematology guideline. Br J Haematol. 2022;198(3):443–458. doi:10.1111/bjh.18239. PMID 35645034
- Arpino PA, Demirjian Z, Van Cott EM. Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin. Pharmacotherapy. 2005;25(2):157–164. doi:10.1592/phco.25.2.157.56950. PMID 15767231
- Astermark J, Miesbach W, Coppens M, et al. Evaluation of one-stage assays for the monitoring of recombinant human factor IX Padua activity after etranacogene dezaparvovec gene therapy. Haemophilia. 2025;31(4):799–806. doi:10.1111/hae.70053. PMID 40534246
- AstraZeneca Pharmaceuticals. ANDEXXA (coagulation factor Xa [recombinant], inactivated-zhzo) prescribing information, sections 5.3, 7.1 and 7.2. DailyMed set ID 2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c, version 7, April 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c
- Augustsson C, Norström E, Andersson NG, Zetterberg E, Astermark J, Strandberg K. Monitoring standard and extended half-life products in hemophilia: assay discrepancies for factor VIII and IX in pre- and postinfusion samples. Res Pract Thromb Haemost. 2020;4(7):1114–1120. doi:10.1002/rth2.12421. PMID 33134777
- Austin JH, Stearns CR, Winkler AM, et al. Use of the chromogenic factor X assay in patients transitioning from argatroban to warfarin therapy. Pharmacotherapy. 2012;32(6):493–501. doi:10.1002/j.1875-9114.2012.01050.x. PMID 22511112
- Badulescu OV, Ciocoiu M, Vladeanu MC, et al. The role of platelet dysfunctions in the pathogenesis of the hemostatic-coagulant system imbalances. Int J Mol Sci. 2025;26(6):2756. doi:10.3390/ijms26062756. PMID 40141398
- Baltaci MA, Aydemir Guloksuz EG, Sak Inal R, et al. Concordance and relative performance of the 2023 ACR/EULAR and revised Sapporo criteria in antiphospholipid syndrome and analysis of risk factors for recurrent thrombosis: a single-center cohort study. Medicina (Kaunas). 2026;62(7):1226. doi:10.3390/medicina62071226. PMID 42512769
- Barbhaiya M, Zuily S, Naden R, et al. The 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol. 2023;75(10):1687–1702. doi:10.1002/art.42624. PMID 37635643. Co-published in Ann Rheum Dis. 2023;82(10):1258–1270. doi:10.1136/ard-2023-224609. PMID 37640450
- Bashir AH, Giordano C, Brennan M. Viscoelastic testing for hemostatic assessment in liver transplantation. J Clin Med. 2026;15(20):7873. doi:10.3390/jcm15207873. PMID 42941387
- Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4(4):e157–e164. doi:10.1016/S2352-3026(17)30026-1. PMID 28259520
- Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369(6475):64–67. doi:10.1038/369064a0. PMID 8164741
- Besser MW, MacDonald SG. Acquired hypofibrinogenemia: current perspectives. J Blood Med. 2016;7:217–225. doi:10.2147/JBM.S90693. PMID 27713652
- Boehringer Ingelheim Pharmaceuticals. PRAXBIND (idarucizumab) injection, prescribing information. DailyMed set ID c7400f8a-dcf4-a6df-6d07-983081b1bf34, version 8, February 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7400f8a-dcf4-a6df-6d07-983081b1bf34
- Bowman M, James P. Diagnosis of von Willebrand disease. Blood Adv. 2025;9(22):5870–5879. doi:10.1182/bloodadvances.2025016485. PMID 40845253
- Bowyer AE, Gosselin RC. Factor VIII and factor IX activity measurements for hemophilia diagnosis and related treatments. Semin Thromb Hemost. 2023;49(6):609–620. doi:10.1055/s-0042-1758870. PMID 36473488
- Brito AMP, Schreiber MA. Precision hemostasis: how viscoelastic testing guides real-time decision-making in trauma. Trauma Surg Acute Care Open. 2026;11(Suppl 1):e002241. doi:10.1136/tsaco-2026-002241. PMID 42094753
- Brohi K, Singh J, Heron M, et al. Acute traumatic coagulopathy. J Trauma. 2003;54(6):1127–1130. doi:10.1097/01.TA.0000069184.82147.06. PMID 12813333
- Bronić A, Coen Herak D, Margetić S, Milić M. Croatian Society of Medical Biochemistry and Laboratory Medicine: national recommendations for blood collection, processing, performance and reporting of results for coagulation screening assays prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen and D-dimer. Biochem Med (Zagreb). 2019;29(2):020503. doi:10.11613/BM.2019.020503. PMID 31223257
- Burley K, Cornish N, Carretero MM, Westbury SK. Testing for non-severe heritable platelet function disorders. Int J Lab Hematol. 2026;48(6):1279–1288. doi:10.1111/ijlh.70192. PMID 42399108
- Castaman G, Bramante Federici A. Von Willebrand disease: classification and epidemiology. Haematologica. 2026;111(1):26–34. doi:10.3324/haematol.2024.286058. PMID 41496701
- Cattaneo M, Cerletti C, Harrison P, et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. J Thromb Haemost. 2013. doi:10.1111/jth.12231. PMID 23574625
- Ch'ng CL, Morgan M, Hainsworth I, et al. Prospective study of liver dysfunction in pregnancy in Southwest Wales. Gut. 2002;51(6):876–880. doi:10.1136/gut.51.6.876. PMID 12427793
- Chang SH, Tillema V, Scherr D. A "percent correction" formula for evaluation of mixing studies. Am J Clin Pathol. 2002;117(1):62–73. doi:10.1309/RREK-8L6M-D2KC-HWLH. PMID 11789732
- Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost. 2007;5(2):266–273. doi:10.1111/j.1538-7836.2007.02297.x. PMID 17087729
- Choufani EB, Sanchorawala V, Ernst T, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood. 2001;97(6):1885–1887. doi:10.1182/blood.v97.6.1885. PMID 11238135
- Cooper PC, Pavlova A, Moore GW, et al. Recommendations for clinical laboratory testing for protein C deficiency, for the subcommittee on plasma coagulation inhibitors of the ISTH. J Thromb Haemost. 2020;18(2):271–277. doi:10.1111/jth.14667. PMID 31999059
- Coppo P, Schwarzinger M, Buffet M, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One. 2010;5(4):e10208. doi:10.1371/journal.pone.0010208. PMID 20436664
- Cox C, Neave L, Hunt BJ. New approaches in the haemostatic management of postpartum haemorrhage. BMJ Med. 2026;5(1):e002256. doi:10.1136/bmjmed-2025-002256. PMID 42299317
- Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360–3392. doi:10.1182/bloodadvances.2018024489. PMID 30482768
- Cuker A, Gimotty PA, Crowther MA, et al. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120(20):4160–4167. doi:10.1182/blood-2012-07-443051. PMID 22990018
- Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90(3):1004–1008. doi:10.1073/pnas.90.3.1004. PMID 8430067
- Deshpande SR, Tarawneh H, Deitelzweig C, et al. Rapid ADAMTS13 activity assays for thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. Blood. 2025;146(2):233–246. doi:10.1182/blood.2025028416. PMID 40258188
- Devreese KMJ, Bertolaccini ML, Branch DW, et al. An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. J Thromb Haemost. 2025;23(2):731–744. doi:10.1016/j.jtha.2024.10.022. PMID 39510414
- Devreese KMJ, de Groot PG, de Laat B, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost. 2020;18(11):2828–2839. doi:10.1111/jth.15047. PMID 33462974
- Doshi BS, Thompson EN, Faig W, Wax A, Obstfeld AE, Lambert MP. Diagnosis of platelet dysfunction in children: clinical predictors and test methods. Blood Vessel Thromb Hemost. 2026;3(1):100135. doi:10.1016/j.bvth.2025.100135. PMID 41623363
- Douxfils J, Adcock DM, Bates SM, et al. 2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2021;121(8):1008–1020. doi:10.1055/a-1450-8178. PMID 33742436
- Douxfils J, Ageno W, Samama CM, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018;16(2):209–219. doi:10.1111/jth.13912. PMID 29193737
- Elbatarny M, Mollah S, Grabell J, et al. Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. Haemophilia. 2014;20(6):831–835. doi:10.1111/hae.12503. PMID 25196510
- Eswaran H, Escobar M, Srivaths L. Diagnostic challenges and frontiers for women and girls with hemophilia / hemophilia carriers: a narrative review. Womens Health (Lond). 2026;22:17455057261494386. doi:10.1177/17455057261494386. PMID 42822846
- Exner T, Michalopoulos N, Pearce J, et al. Simple method for removing DOACs from plasma samples. Thromb Res. 2018;163:117–122. doi:10.1016/j.thromres.2018.01.047. PMID 29407622
- Fatah T, Catella J, Nougier C, Rezigue H. Raising the D-dimer bar: a narrative review of the age-adjusted D-dimer threshold. Res Pract Thromb Haemost. 2026;10(1):103255. doi:10.1016/j.rpth.2025.103255. PMID 41509550
- Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost. 2008;34(8):709–733. doi:10.1055/s-0029-1145254. PMID 19214910
- Favaloro EJ. Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia. Int J Lab Hematol. 2021;43(4):559–570. doi:10.1111/ijlh.13629. PMID 34138513
- Favresse J, Lardinois B, Sabor L, et al. Evaluation of the DOAC-Stop procedure to overcome the effect of DOACs on several thrombophilia screening tests. TH Open. 2018;2(2):e202–e209. doi:10.1055/s-0038-1657785. PMID 31249943
- Frelinger AL 3rd, Rivera J, Connor DE, et al. Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: communication from the ISTH SSC Subcommittee on Platelet Physiology. J Thromb Haemost. 2021;19(12):3193–3202. doi:10.1111/jth.15526. PMID 34580997
- Gando S, Iba T, Eguchi Y, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34(3):625–631. doi:10.1097/01.ccm.0000202209.42491.38. PMID 16521260
- Genentech, Inc. HEMLIBRA (emicizumab-kxwh) injection. US prescribing information. DailyMed, published July 21, 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2483adba-fab6-4d1b-96c5-c195577ed071 (Hemlibra label 2025)
- Genzyme Corporation. QFITLIA (fitusiran) injection. US prescribing information. DailyMed, published September 18, 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6dd2f8ac-6f90-4cbf-b197-97d74964135c (Qfitlia label 2025)
- Gindele R, Kerényi A, Kállai J, et al. Resolving differential diagnostic problems in von Willebrand disease, in fibrinogen disorders, in prekallikrein deficiency and in hereditary hemorrhagic telangiectasia by next-generation sequencing. Life (Basel). 2021;11(3):202. doi:10.3390/life11030202. PMID 33807613
- Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2017;91(3):539–551. doi:10.1016/j.kint.2016.10.005. PMID 27989322
- Gorio C, Molinari AC, Martini T, et al. Hemostasis laboratory diagnostics in newborns. J Clin Med. 2025;14(14):5068. doi:10.3390/jcm14145068. PMID 40725765
- Gosselin RC, Adcock DM, Bates SM, et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2018;118(3):437–450. doi:10.1055/s-0038-1627480. PMID 29433148
- Gosselin RC, Moore GW, Kershaw GW, Montalvão S, Adcock DM. International Council for Standardization in Haematology field study evaluating optimal interpretation methods for activated partial thromboplastin time and prothrombin time mixing studies. Arch Pathol Lab Med. 2024;148(8):880–889. doi:10.5858/arpa.2023-0030-OA. PMID 38031817
- Gould LH, Bopp C, Strockbine N, et al. Recommendations for diagnosis of Shiga toxin-producing Escherichia coli infections by clinical laboratories. MMWR Recomm Rep. 2009;58(RR-12):1–14. PMID 19834454
- Gran C, Frisk T, Homström M, et al. Laboratory assessment of emicizumab levels in hemophilia A: influence of assay selection on reported results. Clin Appl Thromb Hemost. 2025;31:10760296251378458. doi:10.1177/10760296251378458. PMID 41004631
- Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092–2101. doi:10.1056/NEJMoa2104840. PMID 33835769
- Hamedani NS, Oldenburg J, Pötzsch B, Müller J. Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels. PLoS One. 2022;17(7):e0271330. doi:10.1371/journal.pone.0271330. PMID 35834493
- Hickey SE, Curry CJ, Toriello HV. ACMG practice guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. 2013;15(2):153–156. doi:10.1038/gim.2012.165. PMID 23288205
- Hicks LK, Bering H, Carson KR, et al. The ASH Choosing Wisely campaign: five hematologic tests and treatments to question. Blood. 2013;122(24):3879–3883. doi:10.1182/blood-2013-07-518423. PMID 24307720
- Hisada Y. Dysregulated hemostasis in acute promyelocytic leukemia. Int J Hematol. 2024;119(5):526–531. doi:10.1007/s12185-024-03708-0. PMID 38341391
- Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost. 2001;85(6):958–965. PMID 11434702
- Iba T, Di Nisio M, Levy JH, et al. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017;7(9):e017046. doi:10.1136/bmjopen-2017-017046. PMID 28963294
- Iba T, Levy JH, Maier CL, et al. Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation. J Thromb Haemost. 2025;23(7):2356–2362. doi:10.1016/j.jtha.2025.03.038. PMID 40216223
- Iba T, Maier CL, Scarlatescu E, et al. Introducing the new definition and diagnostic criteria of disseminated intravascular coagulation released by the International Society on Thrombosis and Haemostasis in 2025. Semin Thromb Hemost. 2026;52(1):10–17. doi:10.1055/a-2675-6068. PMID 40829630 (cited as Iba 2026a)
- Iba T, Tanigawa T, Kondo Y, et al. Proposal of simplified sepsis-induced coagulopathy criteria (SIC-2) for the detection of early-phase disseminated intravascular coagulation in sepsis. J Thromb Haemost. 2026;24(10):3520–3530. doi:10.1016/j.jtha.2026.07.013. PMID 42498136 (cited as Iba 2026b)
- Iba T, Umemura Y, Watanabe E, et al. Diagnosis of sepsis-induced disseminated intravascular coagulation and coagulopathy. Acute Med Surg. 2019;6(3):223–232. doi:10.1002/ams2.411. PMID 31304023
- Jacobs JW, Booth GS, Costa V, et al. Factor XIII deficiency: a review of biology, testing, and treatment. Clin Hematol Int. 2026;8(1):10–25. doi:10.46989/001c.155180. PMID 41583548 (Jacobs 2026b)
- Jacobs JW, Matafonov A, Baxter PG, et al. Normal thromboelastography with a markedly prolonged activated partial thromboplastin time in severe prekallikrein deficiency: implications for perioperative hemostatic assessment. Transfusion. 2026;66(10):2031–2036. doi:10.1111/trf.70327. PMID 42454615 (Jacobs 2026a)
- James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280–300. doi:10.1182/bloodadvances.2020003265. PMID 33570651
- James PD, Flood VH, Connell NT. 2025 ASH ISTH NBDF WFH monitoring report on the 2021 clinical guidelines on the diagnosis and management of von Willebrand disease. Blood Adv. 2025;9(14):3553–3555. doi:10.1182/bloodadvances.2025016512. PMID 40273329
- Jenkins PV, Bowyer A, Burgess C, et al. Laboratory coagulation tests and emicizumab treatment. A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia. 2020;26(1):151–155. doi:10.1111/hae.13903. PMID 31859415
- Jesiołowski P, Krzywda M, Furmańczyk-Zawiska A, Durlik M. Complement dysregulation in kidney diseases: mechanisms, biomarkers, and emerging targeted therapies. Int J Mol Sci. 2026;27(8):3466. doi:10.3390/ijms27083466. PMID 42074111
- Kalot MA, Husainat N, Abughanimeh O, et al. Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis. Blood Adv. 2022;6(12):3735–3745. doi:10.1182/bloodadvances.2021005431. PMID 35192687
- Kalot MA, Husainat N, Tayiem S, et al. Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy. Blood Adv. 2021;5(23):5023–5031. doi:10.1182/bloodadvances.2021004368. PMID 34597385
- Kitchen S, Adcock DM, Dauer R, et al. International Council for Standardisation in Haematology (ICSH) recommendations for collection of blood samples for coagulation testing. Int J Lab Hematol. 2021;43(4):571–580. doi:10.1111/ijlh.13584. PMID 34097805 (Kitchen 2021a)
- Kitchen S, Adcock DM, Dauer R, et al. International Council for Standardization in Haematology (ICSH) recommendations for processing of blood samples for coagulation testing. Int J Lab Hematol. 2021;43(6):1272–1283. doi:10.1111/ijlh.13702. PMID 34581008 (Kitchen 2021b)
- Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753–764. doi:10.1056/NEJMoa0809329. PMID 19228618
- Kokame K, Nobe Y, Kokubo Y, et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129(1):93–100. doi:10.1111/j.1365-2141.2005.05420.x. PMID 15801961
- Koster T, Blann AD, Briët E, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345(8943):152–155. doi:10.1016/s0140-6736(95)90166-3. PMID 7823669
- Kukreti V, Seftel M, Aguirre MA, et al. American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis. Blood Adv. 2026;10(14):5113–5152. doi:10.1182/bloodadvances.2025017073. PMID 41592868
- Lemarié F, Picard J, Galinat H, et al. Philadelphia-negative myeloproliferative neoplasms and acquired von Willebrand syndrome: only pertinent at diagnosis? Res Pract Thromb Haemost. 2026;10(5):106858. doi:10.1016/j.rpth.2026.106858. PMID 42576955
- Levy JH, Szlam F, Wolberg AS, Winkler A. Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing. Clin Lab Med. 2014;34(3):453–477. doi:10.1016/j.cll.2014.06.005. PMID 25168937
- Li S, Li A, Beckman JA, et al. Discordance between aPTT and anti-Xa in monitoring heparin anticoagulation in mechanical circulatory support. ESC Heart Fail. 2024;11(5):2742–2748. doi:10.1002/ehf2.14816. PMID 38725133
- Lim MY, Ito S, Goshua G, et al. Cost-effectiveness analysis of emicizumab use in hospitalized older individuals with acquired hemophilia A. Blood Vessel Thromb Hemost. 2026;3(4):100195. doi:10.1016/j.bvth.2026.100195. PMID 42733552
- Lippi G, Plebani M, Favaloro EJ. Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. Semin Thromb Hemost. 2013;39(3):258–266. doi:10.1055/s-0032-1328972. PMID 23229354
- Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759–765. doi:10.1111/j.1538-7836.2006.01787.x. PMID 16634744
- Lowe A, Kitchen S, Jennings I, Kitchen DP, Woods TAL, Walker ID. Effects of emicizumab on APTT, FVIII assays and FVIII inhibitor assays using different reagents: results of a UK NEQAS proficiency testing exercise. Haemophilia. 2020;26(6):1087–1091. doi:10.1111/hae.14177. PMID 33094895
- MacDonald S, Pitchford T, Singh D, et al. Diagnosis and monitoring of thrombotic thrombocytopenic purpura: guidance for laboratories from the British Society for Haematology. Br J Haematol. 2026;209(3):928–938. doi:10.1111/bjh.70727. PMID 42605199
- Magnette A, Chatelain M, Chatelain B, Ten Cate H, Mullier F. Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories. Thromb J. 2016;14:49. doi:10.1186/s12959-016-0123-z. PMID 27999475
- Marchetti M, Zermatten MG, Bertaggia Calderara D, et al. Heparin-induced thrombocytopenia: a review of new concepts in pathogenesis, diagnosis, and management. J Clin Med. 2021;10(4):683. doi:10.3390/jcm10040683. PMID 33578859
- Marco-Rico A. Update on the laboratory diagnosis of lupus anticoagulant: current challenges and clinical involvement. J Clin Med. 2025;14(8):2791. doi:10.3390/jcm14082791. PMID 40283621
- Marlar RA, Potts RM, Marlar AA. Effect on routine and special coagulation testing values of citrate anticoagulant adjustment in patients with high hematocrit values. Am J Clin Pathol. 2006;126(3):400–405. doi:10.1309/RRQKT2JEYV33D19D. PMID 16880137
- Matsuoka T, Yamakawa K, Umemura Y, et al. The transition of the criteria for disseminated intravascular coagulation and the targeted patients in randomized controlled trials over the decades: a scoping review. Thromb J. 2024;22(1):112. doi:10.1186/s12959-024-00681-w. PMID 39716150
- Medical Advisory Secretariat. Point-of-care international normalized ratio (INR) monitoring devices for patients on long-term oral anticoagulation therapy: an evidence-based analysis. Ont Health Technol Assess Ser. 2009;9(12):1–114. PMID 23074516
- Meng C, Halkidis K. The landscape of ADAMTS13-related tests in thrombotic thrombocytopenic purpura: a review. Front Med (Lausanne). 2026;13:1829389. doi:10.3389/fmed.2026.1829389. PMID 42145720
- Meroni PL, Borghi MO, Amengual O, et al. 2023 American College of Rheumatology/European League Against Rheumatism antiphospholipid syndrome classification criteria solid phase-based antiphospholipid antibody domain: collaborative efforts of APS ACTION and ISTH SSC to harmonize ELISA and non-ELISA antiphospholipid antibody tests. J Thromb Haemost. 2025;23(1):341–344. doi:10.1016/j.jtha.2024.09.021. PMID 39395544
- Meroni PL, Borghi MO, Amengual O, et al. Erratum to the 2023 ACR/EULAR solid phase-based antiphospholipid antibody domain communication. J Thromb Haemost. 2026;24(3):1209–1210. doi:10.1016/j.jtha.2026.01.001. PMID 41535144
- Meyer AL, Malehsa D, Budde U, Bara C, Haverich A, Strueber M. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail. 2014;2(2):141–145. doi:10.1016/j.jchf.2013.10.008. PMID 24720921
- Mezzano D, Harrison P, Frelinger AL 3rd, et al. Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: communication from the ISTH SSC Subcommittee on Platelet Physiology. J Thromb Haemost. 2022;20(9):2127–2135. doi:10.1111/jth.15781. PMID 35770723
- Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023;7(22):7101–7138. doi:10.1182/bloodadvances.2023010177. PMID 37195076
- Miller CH. Laboratory testing for factor VIII and IX inhibitors in haemophilia: a review. Haemophilia. 2018;24(2):186–197. doi:10.1111/hae.13424. PMID 29446525
- Mirus M, Heubner L, Kalbhenn J, Spieth PM. Hemostatic disorders associated with extracorporeal membrane oxygenation. Minerva Anestesiol. 2023;89(6):586–596. doi:10.23736/S0375-9393.23.17121-5. PMID 37283541
- Mithoowani S, Tan CW, Siegal DM. Measuring direct oral anticoagulant (DOAC) levels: applications, limitations, and future directions. Int J Lab Hematol. 2026;48(2):250–258. doi:10.1111/ijlh.14483. PMID 40260639
- Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306. doi:10.1111/j.1538-7836.2006.01753.x. PMID 16420554
- Mohsenian S, Cairo A, Palla R, et al. Genetic and laboratory predictors of bleeding severity in FVII deficiency: insights from the PRO-RBDD and EN-RBD databases. Blood Adv. 2026;10(21):7187–7196. doi:10.1182/bloodadvances.2026020732. PMID 42480507
- Monagle P, Barnes C, Ignjatovic V, et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost. 2006;95(2):362–372. doi:10.1160/TH05-01-0047. PMID 16493500
- Moore GW, Jones PO, Platton S, et al. International multicenter, multiplatform study to validate Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test. J Thromb Haemost. 2021;19(12):3177–3192. doi:10.1111/jth.15438. PMID 34192404
- Moore HB, Moore EE, Huebner BR, et al. Fibrinolysis shutdown is associated with a fivefold increase in mortality in trauma patients lacking hypersensitivity to tissue plasminogen activator. J Trauma Acute Care Surg. 2017;83(6):1014–1022. doi:10.1097/TA.0000000000001718. PMID 29190254
- Nagler M, Bachmann LM, ten Cate H, et al. Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2016;127(5):546–557. doi:10.1182/blood-2015-07-661215. PMID 26518436
- Nakashima MO, Rogers HJ. Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants. Blood Res. 2014;49(2):85–94. doi:10.5045/br.2014.49.2.85. PMID 25025009
- Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171–232. doi:10.1111/j.1365-2516.2007.01643.x. PMID 18315614
- Ninivaggi M, de Laat-Kremers R, Tripodi A, et al. Recommendations for the measurement of thrombin generation: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. J Thromb Haemost. 2021;19(5):1372–1378. doi:10.1111/jth.15287. PMID 33880866
- Novelli C, Vidali M, Brando B, et al. A collaborative study by the Working Group on Hemostasis and Thrombosis of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC) on the interference of haemolysis on five routine blood coagulation tests by evaluation of 269 paired haemolysed/non-haemolysed samples. Biochem Med (Zagreb). 2018;28(3):030711. doi:10.11613/BM.2018.030711. PMID 30429679
- Novo Nordisk. ALHEMO (concizumab-mtci) injection. US prescribing information. DailyMed, published August 15, 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=156f6404-1f6f-417f-bcf8-f07a27a82cc1 (Alhemo label 2025)
- Ozment C, Alexander PMA, Chandler W, et al. Anticoagulation monitoring and targets: the Pediatric Extracorporeal Membrane Oxygenation Anticoagulation CollaborativE Consensus Conference. Pediatr Crit Care Med. 2024;25(7 Suppl 1):e14–e24. doi:10.1097/PCC.0000000000003494. PMID 38959356
- Par Health USA. Argatroban injection, prescribing information, sections 2.3, 2.5, 7.1, 7.2, 12.1, 12.2 and 12.3 (revised May 2026). DailyMed set ID 1a67a87d-59cb-414c-a11e-ab8f0a9bb778. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a67a87d-59cb-414c-a11e-ab8f0a9bb778
- Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714–4718. doi:10.1182/blood-2011-03-340232. PMID 21765019
- Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009;7(10):1737–1740. doi:10.1111/j.1538-7836.2009.03555.x. PMID 19624461
- Pishko AM, Frere C, Maier CL, et al. Management of anticoagulation in patients with heparin-induced thrombocytopenia requiring cardiac surgery with cardiopulmonary bypass: guidance from the ISTH SSC on Perioperative and Critical Care Haemostasis and Thrombosis. J Thromb Haemost. 2026;24(9):3369–3391. doi:10.1016/j.jtha.2026.05.029. PMID 42248416
- Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AH, et al. Bleeding in carriers of hemophilia. Blood. 2006;108(1):52–56. doi:10.1182/blood-2005-09-3879. PMID 16551972
- Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal: full cohort analysis. N Engl J Med. 2017;377(5):431–441. doi:10.1056/NEJMoa1707278. PMID 28693366
- Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88(10):3698–3703. doi:10.1182/blood.v88.10.3698.bloodjournal88103698. PMID 8916933
- Reardon B, Pasalic L, Lippi G, et al. Heparin anticoagulant therapy and its monitoring. Biomolecules. 2026;16(3):425. doi:10.3390/biom16030425. PMID 41897360
- Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014;311(11):1117–1124. doi:10.1001/jama.2014.2135. PMID 24643601
- Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8(9):2063–2065. doi:10.1111/j.1538-7836.2010.03975.x. PMID 20626619
- Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost. 1987;57(2):144–147. PMID 3110995
- Saadalla A, Doyle K, Moser K, Smock K. Determination of fibrinogen ratio cutoff limits using indirect reference interval methodology. Int J Lab Hematol. 2025;47(6):1171–1177. doi:10.1111/ijlh.14526. PMID 40631616
- Safdari SM, Jozdani S, Mottaghizadeh-Jazi M, et al. Molecular diagnosis of inherited platelet disorders: a tale of two realities - advanced vs. resource-limited setting. Thromb J. 2025;23(1):119. doi:10.1186/s12959-025-00797-7. PMID 41316200
- Salazar E, Smock KJ, Cazzolli T, et al. D-dimer reporting and harmonization: analysis of College of American Pathologists D-dimer proficiency testing program. Semin Thromb Hemost. 2026;52(8):975–981. doi:10.1055/a-2803-3165. PMID 41651008
- Santacroce R, D'Andrea G, Tiscia GL, et al. Clinical and genetic heterogeneity of factor XI deficiency: insights from a southern Italian cohort. Int J Mol Sci. 2025;26(18):8807. doi:10.3390/ijms26188807. PMID 41009375
- Santorino D, Siedner MJ, Mwanga-Amumpaire J, Shearer MJ, Harrington DJ, Wariyar U. Prevalence and predictors of functional vitamin K insufficiency in mothers and newborns in Uganda. Nutrients. 2015;7(10):8545–8552. doi:10.3390/nu7105408. PMID 26501317
- Schönborn L, Thiele T, Esefeld M, et al. Quantitative interpretation of PF4/heparin-EIA optical densities in predicting platelet-activating VITT antibodies. J Thromb Haemost. 2022;20(11):2579–2586. doi:10.1111/jth.15862. PMID 36006172
- Scully M, Rayment R, Clark A, et al. A British Society for Haematology guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies. Br J Haematol. 2023;203(4):546–563. doi:10.1111/bjh.19026. PMID 37586700
- Seidizadeh O, Cairo A, Othman M, Peyvandi F. Global prevalence of platelet-type von Willebrand disease. Res Pract Thromb Haemost. 2025;9(1):102682. doi:10.1016/j.rpth.2025.102682. PMID 39975577
- Sheng T, Tang Y, Tan Z, et al. Reclassification of obstetric antiphospholipid syndrome under the 2023 ACR/EULAR criteria: risk of under-recognition in patients with non-criteria antibodies and clinical implications. Front Med (Lausanne). 2026;13:1929786. doi:10.3389/fmed.2026.1929786. PMID 42827817
- Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67(1):27–30. PMID 3940551
- Shima M, Fukutake K, Ogawa Y, et al. Real-world use of emicizumab in patients with acquired haemophilia A: an interim safety analysis of a large-scale post-marketing surveillance study. Haemophilia. 2026;32(4):933–942. doi:10.1111/hae.70301. PMID 42059144
- Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373(25):2413–2424. doi:10.1056/NEJMoa1510991. PMID 26559317
- Siriez R, Dogné JM, Gosselin R, et al. Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: practical recommendations for the laboratory. Int J Lab Hematol. 2021;43(1):7–20. doi:10.1111/ijlh.13342. PMID 32946681
- Song J, Zeng J, Song X. Case report: thrombotic and haemorrhagic disseminated intravascular coagulation in COVID-19. Front Med (Lausanne). 2026;13:1999533. doi:10.3389/fmed.2026.1999533. PMID 42922967
- Su M, Yates S, Sanchez M, Shen YM. Emicizumab in the treatment of acquired hemophilia A: a two-center experience. Ann Hematol. 2026;105(4):150. doi:10.1007/s00277-026-06905-5. PMID 41762246
- Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62(24):2261–2273. doi:10.1016/j.jacc.2013.07.101. PMID 24076493
- Taylor FB Jr, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327–1330. PMID 11816725
- Tiede A, Collins P, Knoebl P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020;105(7):1791–1801. doi:10.3324/haematol.2019.230771. PMID 32381574
- Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood. 2011;117(25):6777–6785. doi:10.1182/blood-2010-11-297580. PMID 21540459
- Tosetto A, Eikenboom J. Clinical and laboratory diagnosis of von Willebrand disease. Haematologica. 2026;111(1):35–43. doi:10.3324/haematol.2024.286011. PMID 41496702
- Tripodi A, Cohen H, Devreese KMJ. Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020;18(7):1569–1575. doi:10.1111/jth.14846. PMID 32619349
- Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005;41(3):553–558. doi:10.1002/hep.20569. PMID 15726661
- Trivedi C, Hsu A. Microangiopathic hemolytic anemia in pregnancy. J Brown Hosp Med. 2025;4(3):137995. doi:10.56305/001c.137995. PMID 40612089
- Uriel N, Pak SW, Jorde UP, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol. 2010;56(15):1207–1213. doi:10.1016/j.jacc.2010.05.016. PMID 20598466
- Van Cott EM, Orlando C, Moore GW, et al. Recommendations for clinical laboratory testing for antithrombin deficiency; communication from the SSC of the ISTH. J Thromb Haemost. 2020;18(1):17–22. doi:10.1111/jth.14648. PMID 31894660
- van Galen KPM, d'Oiron R, James P, et al. A new hemophilia carrier nomenclature to define hemophilia in women and girls: communication from the SSC of the ISTH. J Thromb Haemost. 2021;19(8):1883–1887. doi:10.1111/jth.15397. PMID 34327828
- Van Laer C, Moore GW, Majumder R, et al. Survey on current practice in thrombophilia testing: from phenotype to genotype. Communication from the SSC of the ISTH. J Thromb Haemost. 2026;24(3):1171–1180. doi:10.1016/j.jtha.2025.10.032. PMID 41238194
- van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–1127. doi:10.1160/TH09-11-0758. PMID 20352166
- Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73(2):247–251. PMID 7792738
- Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003;349(4):343–349. doi:10.1056/NEJMoa022831. PMID 12878741
- Volod O, Bunch CM, Zackariya N, et al. Viscoelastic hemostatic assays: a primer on legacy and new generation devices. J Clin Med. 2022;11(3):860. doi:10.3390/jcm11030860. PMID 35160311
- Warkentin TE, Sheppard JI, Moore JC, et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008;6(8):1304–1312. doi:10.1111/j.1538-7836.2008.03025.x. PMID 18489711
- Westafer LM, Long B, Gottlieb M. Managing pulmonary embolism. Ann Emerg Med. 2023;82(3):394–402. doi:10.1016/j.annemergmed.2023.01.019. PMID 36805291
- White D, Moore GW, Besser M, et al. Direct oral anticoagulants-Remove versus Taipan snake venom time for detection of a lupus anticoagulant in patients taking oral direct factor Xa inhibitors. Res Pract Thromb Haemost. 2022;6(1):e12648. doi:10.1002/rth2.12648. PMID 35106431
- Yates SG, Webb CB, Scheid LM, et al. Performance evaluation of a reflexive algorithm for suspected heparin-induced thrombocytopenia. Res Pract Thromb Haemost. 2026;10(5):106866. doi:10.1016/j.rpth.2026.106866. PMID 42572566
- Yoon I, Han JH, Jeon HJ. Advances in platelet-dysfunction diagnostic technologies. Biomolecules. 2024;14(6):714. doi:10.3390/biom14060714. PMID 38927117
- Yu ES, Jeon MJ, Kang KW, et al. The role of platelet function analyzer-200 in predicting perioperative bleeding risk. Korean J Intern Med. 2020;35(5):1199–1209. doi:10.3904/kjim.2019.112. PMID 32019292
- Zetterberg E, Strandberg K, Hillarp A, et al. Acquired von Willebrand syndrome: a comprehensive review and a Nordic perspective. Semin Thromb Hemost. 2026;52(6):628–644. doi:10.1055/a-2765-9556. PMID 41429124
- Zheng XL, Al-Housni Z, Cataland SR, et al. 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2025;23(11):3711–3732. doi:10.1016/j.jtha.2025.06.002. PMID 40533296
- Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2486–2495. doi:10.1111/jth.15006. PMID 32914582
- Zheng Z, Mukhametova L, Boffa MB, et al. Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis. J Thromb Haemost. 2023;21(4):1043–1054. doi:10.1016/j.jtha.2023.01.008. PMID 36759279
- Zhou T, Cheng W, Jiang G, et al. Admission antithrombin III activity as a risk-enrichment marker for septic shock below the ISTH overt-DIC threshold. Front Med (Lausanne). 2026;13:1899792. doi:10.3389/fmed.2026.1899792. PMID 42602135
- Zini G, d'Onofrio G, Briggs C, et al. ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes. Int J Lab Hematol. 2012;34(2):107–116. doi:10.1111/j.1751-553X.2011.01380.x. PMID 22081912
- Zini G, d'Onofrio G, Erber WN, et al. 2021 update of the 2012 ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes: impact and revisions. Int J Lab Hematol. 2021;43(6):1264–1271. doi:10.1111/ijlh.13682. PMID 34431220
- Zou JM, Li TJ, Liu Q, Hu YG. Challenges in PT/INR harmonization across the total testing process. Biochem Med (Zagreb). 2026;36(3):030504. doi:10.11613/BM.2026.030504. PMID 42828232